==> picture [100 x 41] intentionally omitted <==

Pfizer Limited

The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

June 29, 2025

The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1[st] Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Plot No. C/1, Dalal Street, Fort G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 500680 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Business Responsibility & Sustainability Report for the Financial Year 2024 – 25.

Ref: Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

In compliance with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we submit herewith the Business Responsibility & Sustainability Report for the financial year 2024-25, which also forms part of the Annual Report for financial Year 2024-25, submitted to the Exchanges vide letter dated June 29, 2025.

Please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

Digitally signed by Prajeet Nair Prajeet Nair Date: 2025.06.29 22:29:47 +05'30'

Prajeet Nair

Director – Corporate Services & Company Secretary

CIN: L24231MH1950PLC008311 Email ID: [email protected] Website: www.pfizerltd.co.in

Annexure – G BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT (“BRSR”)

Pfizer Limited, (“the Company”) being a subsidiary of Pfizer Inc., USA, one of the world’s premier biopharmaceutical companies, understands the significance of our role in helping address healthcare challenges in India while upholding ethical standards and environmental stewardship. As Pfizer globally embarks on its 175[th] year of operations as one of the world’s most trusted and innovative healthcare companies, we are determined to outdo yesterday by remaining committed not only to advancing our Purpose, but to being a good corporate citizen.

We continue to stand by our commitment towards contributing to long-term value creation and a sustainable, responsible, and patient centric business model. Our focus is rooted in our purpose to deliver Breakthroughs that change patients’ lives through ethical decision-making and our core values — Courage, Excellence, Equity, and Joy .

This Business Responsibility and Sustainability Report (“BRSR”) for the financial year 2024-25 seeks to disclose our performance against the nine principles of the “National Guidelines on Responsible Business Conduct” (“NGRBC”). These nine principles are further divided in the BRSR into Essential Indicators and Leadership Indicators.

Further, for reporting purposes, we have developed certain methodologies and used certain assumptions, in line with the Guidance Note prescribed by the Securities and Exchange Board of India. These methodologies and assumptions will continue to be reviewed and refined as the regulatory framework governing BRSR evolves in India.

Section A: General Disclosures

I. Details of the listed entity:

S. No.	Question	Response
1.	Corporate IdentityNumber (CIN) of the Listed Entity	L24231MH1950PLC008311
2.	Name of the Listed Entity	Pfizer Limited
3.	Year of Incorporation	1950
4.	Registered Office Address	The Capital, 1802/1901, Plot No. C - 70,
		G Block, Bandra Kurla Complex,
		Bandra (East), Mumbai, 400051.
5.	Corporate Address	Same as above.
6.	E-mail	[email protected]
7.	Telephone	+91 22 6693 2000
8.	Website	http://www.pfizerltd.co.in
9.	Financial Year for which reportingis beingdone	April 1, 2024 – March 31, 2025
10.	Name of the Stock Exchange(s) where shares are	• BSE Limited (BSE)
	listed	• National Stock Exchange of India Limited (NSE)
11.	Paid-upCapital (INR.)	`45,74,77,320/-
12.	Name and contact details (telephone & email) of the	Mr. Prajeet Nair
	person who may be contacted in case of queries on	Director - Corporate Services & Company Secretary
	the BRSR report	Tel: +91 22 6693 2000
		Email:[email protected]
13.	Reporting Boundary	Standalone
	(Standalone or Consolidated basis)
14.	Name of assuranceprovider	Not applicable
15.	Type of assurance obtained	Not applicable

II. Products/ Services:

16. Details of business activities (accounting for 90% of the turnover):

S. No.	Description of Main Activity	Description of Business Activity	% Turnover of the entity
1.	Pharmaceuticals	Manufacturing, marketing, distribution and	93.04
		tradingofpharmaceuticalproducts.

17. Product/ Services sold by the entity (accounting for 90% of the entity’s turnover):

S. No.	Product/ Service	NIC Code	% of total Turnover contributed
1.	Pharmaceuticalproducts	21002	93.04%

III. Operations:

18. Number of locations where plants and/or operations/ offices of the entity are situated:

Location	Number of Plants	Number of Offices*	Total
National	1	2	3
International	–	–	–

*Offices as on March 31, 2025

Hyphen (-) appearing in the Report denotes “Nil/ Zero”.

19. Markets Served by the Entity:

a. Number of Locations:

kets Served by the Entity: Number of Locations:
Location	Number
National (No. of States)	28 States and 8 Union Territories
International (No. of Countries)	5
	(Nepal, Sri Lanka, Bangladesh, Ireland and Netherlands)

b. What is the contribution of exports as a percentage of the total turnover of the entity?

The contribution of exports as a percentage of total turnover of the Company is 5% during the reporting period FY 2024-25.

c. A Brief on types of customers?

Patients are our North Star. Our ultimate customers are patients who use our medicines; our other customers include distributors, stockists, healthcare professionals, hospitals, caregivers, and government institutions.

IV. Employees:

20. Details as at March 31, 2025:

a. Employees and Workers

ployees: ails as at March 31, 2025: Employees and Workers
S. No. Particulars Total (A)	Male Female
	Number (B) Percentage (B/A) Number (B) Percentage (B/A)
	Employees (including differently abled)
1. Permanent Employees 1,563	1,316 84% 247 16%
2. Other than Permanent Employees 170	80 47% 90 53%
3. Total Employees(1+2) 1,733	1,396 81% 337 19%
	Workers (including differently abled)
4. Permanent Workers 35	35 100% – –
5. Other than Permanent Workers –	– – – –
6. Total Workers(4+5) 35	35 100% – –

b. Differently abled Employees and Workers

Differently abled Employees and Workers
S. No. Particulars Total (A)	Male Female
	Number (B) Percentage (B/A) Number (B) Percentage (B/A)
	Differently Abled Employees
1. Permanent Employees –	– – – –
2. Other than Permanent Employees –	– – – –
3. Total Employees (1+2) –	– – – –
	Differently Abled Workers
4. Permanent Workers –	– – – –
5. Other than Permanent Workers –	– – – –
6. Total Workers (4+5) –	– – – –

21. Participation/ Inclusion/ Representation of Women:

	Total (A)	Number of Female (B)	Percentage (B/A)
Board of Directors	7	3	43%
Key Management Personnel (KMP)	4	1	25%

22. Turnover rate for permanent employees and workers:

	FY 2024- 25 FY 2023- 24 FY 2022- 23	FY 2024- 25 FY 2023- 24 FY 2022- 23	FY 2024- 25 FY 2023- 24 FY 2022- 23	FY 2024- 25 FY 2023- 24 FY 2022- 23
	Male Female Total Male Female Total Male Female Total
Permanent Employees	14%	19%	15%	14% 17% 15% 49% 35% 47%*
Permanent Workers	–	–	–	5% – 5% 62% 90% 63%**

Higher turnover ratio for FY 2022-23 is on account of voluntary and involuntary separation of employees due to sale of Upjohn.

** Workers turnover rate for the FY 2022-23 is calculated by dividing the number of workers leaving employment during the FY 2022-23 with the total number of workers at the beginning of the FY 2022-23 to show a realistic value.

Business, sale of Thane Business Undertaking and restructuring to drive business transformation. Excluding the above factors, the voluntary permanent employees, and workers turnover rate for the FY 2022 – 23 would be as follows:

	Male	Female	Total
Permanent Employees	14%	21%	15%
Permanent Workers	4%	–	4%

V. Holding, Subsidiary and Associate Companies (including joint ventures):

23. (a). Names of holding/ subsidiary/ associate companies/ joint ventures

S.	Name of the holding/ subsidiary/	Indicate whether	% of shares	Does the entity indicated
No.	associate company/ joint venture (A)	holding/ subsidiary/	held by	at Column A, participate in
		associate company/	listed entity	the Business Responsibility
		joint venture		initiatives of the entity
				(Yes/ No)
1.	Pfizer Inc., USA	Ultimate Holding	–	No
		Company
2.	Pfizer East India B.V., Netherlands	HoldingCompany	–	No
3.	Wyeth LLC., USA	HoldingCompany	–	No
4.	Wyeth Holdings LLC, USA	HoldingCompany	–	No
5.	Warner-Lambert CompanyLLC, USA	HoldingCompany	–	No
6.	Parke, Davis & CompanyLLC, USA	HoldingCompany	–	No
7.	John Wyeth & Brother Ltd, UK	HoldingCompany	–	No
8.	Pharmacia LLC, USA	HoldingCompany	–	No

Hyphen (-) appearing in the Report denotes “Nil/ Zero”.

VI. CSR (Corporate Social Responsibility) Details:

24. (i) Whether CSR is applicable as per Section 135 of Companies Act, 2013 (Yes/No): Yes

(ii) Turnover : ` 2,281.35 Crore
(iii) Net Worth : ` 4,217.41 Crore

Transparency and Disclosures Compliances:

25. Complaints/ Grievances on any of the Principles (1-9) under the National Guidelines on Responsible Business Conduct:

Stakeholder Group Grievance Redressal Mechanism in place (Y/N) (Provide web-link of policy)	Current Financial Year 2024- 25	Current Financial Year 2024- 25	Current Financial Year 2024- 25	Previous Financial Year 2023- 24
	Number of complaints filed	Number of complaints pending at close of year	Remarks	Number of complaints filed Number of complaints pending at close of year Remarks
Communities Yes https://www.pfizerltd.co.in/files/ Pfizer_2023BlueBook.pdf	–	–	–	– – –
Investors (Other than shareholders) Not applicable
Shareholders Yes https://www.pfizerltd.co.in/ investor-grievance-redressal	111	3	Three pending complaints were resolved subsequently within the prescribed timelines	128 1 One pending complaint was resolved subsequently within the prescribed timelines
Employees and Workers Yes https://www.pfizerltd.co.in/files/ Pfizer_2023BlueBook.pdf https://www.pfizerltd.co.in/ whistle-blower-vigil-mechanism	71	3	–	63 1 –

Stakeholder Group Grievance Redressal Mechanism in place (Y/N) (Provide web-link of policy)	Current Financial Year 2024- 25 Previous Financial Year 2023- 24	Current Financial Year 2024- 25 Previous Financial Year 2023- 24	Current Financial Year 2024- 25 Previous Financial Year 2023- 24	Current Financial Year 2024- 25 Previous Financial Year 2023- 24
	Number of complaints filed Number of complaints pending at close of year Remarks Number of complaints filed Number of complaints pending at close of year Remarks
Consumers Yes https://www.pfizerltd.co.in/files/ Pfizer_2023BlueBook.pdf https://www.pfizerltd.co.in/ whistle-blower-vigil-mechanism	149	16	The pending complaints are under investigation	208 5 –
Value Chain partners Yes https://www.pfizerltd.co.in/files/ Pfizer_2023BlueBook.pdf https://www.pfizerltd.co.in/ whistle-blower-vigil-mechanism https://www.pfizerltd.co.in/ contact	162	–	Received under customer relationship management (CRM) program	1 – –
Others (Media, contractor, third party vendor, HCP, anonymous, etc.) Yes https://www.pfizerltd.co.in/files/ Pfizer_2023BlueBook.pdf https://www.pfizerltd.co.in/ whistle-blower-vigil-mechanism https://www.pfizerltd.co.in/ contact	19	0	–	25 1 –

Hyphen (-) appearing in the Report denotes “Nil/ Zero”.

26. Overview of the entity’s material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format:

Our parent company Pfizer Inc. completed an assessment to identify priorities related to responsible business growth, in alignment with corporate strategy. As part of the process, Pfizer Inc. identified 30 key topics, which were mapped into six priority areas. These priority areas are aligned with our Parent Company’s Blueprint Strategy and are further incorporated into its Enterprise Risk Management (ERM) process. These six areas are consistent with our Values and our patient centered purpose.

In line with our Parent Company, Pfizer Limited has identified the following ESG priorities. Please see - Pfizer’s enterprise Impact Report (https://cdn.pfizer.com/pfizercom/Pfizer_2024_Impact_Report Performance_ Data_02JUN2025.pdf) for enterprise-level information and description of Pfizer’s ESG priority areas. The information that follows is based on locally identified responsible business conduct issues.

S.	Material Issue	Indicate	Rationale for identifying the risk/	In	case of Risk, approach to adapt or	Financial Implications of
No.	Identified	whether Risk	opportunity	mitigate		the risk or the opportunity
		or Opportunity				(Negative/ Positive)
		(R/O)
1.	Climate	Risk	At Pfizer, we are committed to	1.	The Company, through its parent	Positive:
	Change		reducing our environmental footprint, conserving resources, and reducing waste arising from our operations. We recognize that climate change poses significant risks to global health as well as to our business operations.		company, Pfizer Inc., aims to continue its near term commitment to reduce greenhouse gas (GHG) emissions by 46% compared to 2019 baseline, aligned with a 1.50C trajectory. Pfizer Inc. also aims to reduce GHG emissions by working to achieve the voluntary Net Zero Standard by 2040, 10 years earlier than the timeline prescribed in the standard. We aim to decrease GHG emissions by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.	The Company’s focus on its climate change related goals helps enable it to reduce environmental risks and create a resilient business. Through replacing our capital assets to become more efficient and use alternative fuel sources, Pfizer could increase resilience to volatile fuel and energy prices resulting from the low-carbon transition and increase returns on investment in low emissions technology.
				2.	Pfizer Limited installed a strategic,
					multi-phase 1,500 KWp solar
					project at its Goa manufacturing
					facility. The site generated 2596
					MWH Green Electricity in the
					financial year 2024-25 out of which
					1,803 MWH electrical energy
					was consumed in manufacturing
					process and 793 MWH was
					exported back to National Grid.
2.	Product	Risk &	Patient health and safety are	Product quality and safety are		Positive: Emphasis on
	Quality and	Opportunity	foundational to everything we	paramount to the Company and the		quality and safety allows us
	Safety		do. Our commitment to health	Company’s approach to mitigate risks		to build strong and lasting
			& safety allows us to cater	includes the following:		relationships with our
			excellence through our products. The safety of our customers and patients is of the utmost importance. This has a critical impact on our relationships with stakeholders.	1.	The Quality Management System (“QMS”) of the Company is based on industry-recognized quality management principles and is designed and built to adhere to applicable standards and	stakeholders. This furthers our business objectives and allows for continued financial growth. Negative: Failure to maintain high quality in
			Failure to maintain product		requirements of health authorities	products could adversely
			quality and product safety may		and best practices.	impact patient health,
			have an adverse impact on the well-being of the patients, reputation of the Company, and may expose the Company to	2.	The Company provides training to employees in product safety and quality.	reputational damage, financial liability, product recalls and shortages.
			litigation.	3.	The grievance redressal
					mechanism of the Company
					enables complaints to be raised
					relating to product quality in a
					timelymanner.

S.	Material Issue	Indicate	Rationale for identifying the risk/	In case of Risk, approach to adapt or	Financial	Financial	Implications	Implications	Implications	Implications	Implications	Implications	Implications	of
No.	Identified	whether Risk	opportunity	mitigate	the risk or			the		opportunity
		or Opportunity			(Negative/ Positive)
		(R/O)
3.	Colleague	Opportunity	Colleague Diversity, Equity, and	Not applicable	Positive:
	Diversity, Equity and Inclusion		Inclusion (“DEI”) is core to the Company. At Pfizer, we believe every person deserves to be seen, heard, and cared for. This		DEI has a positive impact on the Company’s workforce, operations, and business.
			belief drives our refreshed Global
			DEI strategy launched in 2021,
			focused on building a more
			inclusive colleague experience,
			advancing equitable health
			outcomes, and transforming
			society through external
			partnerships. The Diversity
			and Inclusion Council of Pfizer
			Limited acts as a think tank that
			gives shape to the DEI initiatives
			to bring positive effects in the
			work environment.
			The Company also strives to
			ensure that our workplaces
			are designed and equipped to
			support anyone with a disability
			(PWD) so that all colleagues are
			suitably supported. In addition,
			We are committed to equal
			opportunities in the terms and
			conditions of employment for
			all employees and job applicants
			with no discrimination and
			without regard to race, color,
			religion, sex, sexual orientation,
			age, gender identity or gender
			expression, national origin, or
			disability.
4.	Equitable	Opportunity	The Company is committed	Not applicable	Positive:			The			Company
	Access and		to enhancing the access and		continually								leads
	Pricing		affordability and pricing of its		engagement						initiatives
			portfolio of medicines to patients		with	key			government
			who may need them. Towards		stakeholders				by	advocating
			this end, the Company actively		for policies					aimed				at
			engages with all stakeholders,		enhancing				access					to
			including policy makers to		medicines.						Expanded
			expand access opportunities.		access,				affordability
					and appropriate							pricing
					creates		an		opportunity
					for the	Company to							reach
					more	patients,						thereby
					benefiting			the		community
					as well as		having				a	positive
					impact	on		the		Company’s
					business.

S. Material Issue Indicate Rationale for identifying the risk/ In case of Risk, approach to adapt or Financial Implications of No. Identified whether Risk opportunity mitigate the risk or the opportunity or Opportunity (Negative/ Positive) (R/O) 5. Business Risk & Values-based decision making Our Code of Conduct (the Blue Book) and Positive : Pfizer is Ethics Opportunity Promotes accountability and related policies, procedures, and training committed to conducting helps ensure that integrity, are designed to support compliance business responsibly quality, safety, and ethics are and adherence to our Values - Courage, and acting ethically, foundational to all we do. Excellence, Equity, and Joy. in accordance with all applicable laws and Policies governing colleague interactions regulations. Ethical with healthcare organizations, decisions promote trust physicians, patients, and other and accountability for stakeholders are contained in the Blue doing the right thing, both Book. internally and externally. In To ensure that business ethics is doing so, we demonstrate integrated into our business, we have our continued commitment in place strong policies such as our to living our Values and Code of Conduct and Ethics Policy. Any earning the trust of the violations of the same can be addressed patients we serve and through our Whistleblower Policy/ Vigil to fully realize Pfizer’s Mechanism. Additionally, Pfizer’s My Purpose - Breakthroughs Anti-Corruption Policy and Procedures That Change Patients’ (“MAPP”) outline Pfizer’s enterpriseLives. wide approach to preventing bribery and Negative : Violations of corruption. business ethics principles can lead to reputational damage and subsequent financial implications. These can be in the form of fines and penalties. 6. Product Opportunity Reduce cycle times, increase Not applicable Positive: As the global Innovation success rates, and get more health landscape continues breakthroughs into the hands of to evolve, Pfizer Inc., our patients sooner. Parent Company aims to uncover new combinations, designs, and advances to help address an array of challenges by making innovation as one of its greatest tools.

Section B: Management and Process Disclosures

The National Guidelines for Responsible Business Conduct (NGRBC) as prescribed by the Ministry of Corporate Affairs advocates nine principles referred as P1-P9 as given below:

Principle	Description
Principle 1	Businesses should conduct and govern themselves with integrity in a manner that is ethical, transparent,
	and accountable.
Principle 2	Businesses should provide goods and services in a manner that is sustainable and safe.
Principle 3	Businesses should respect and promote the well-being of all employees, including those in their value
	chains.
Principle 4	Businesses should respect the interests of and be responsive to all its stakeholders.
Principle 5	Businesses should respect and promote human rights.
Principle 6	Businesses should respect and make efforts to protect and restore the environment.
Principle 7	Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is
	responsible and transparent.
Principle 8	Businesses should promote inclusive growth and equitable development.
Principle 9	Businesses should engage with and provide value to their consumers in a responsible manner.

This section is aimed at helping businesses demonstrate the structures, policies, and processes out in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	Disclosure Questions	P1	P2 P3 P4 P5 P6	P7	P8	P9
Policy and Management Processes
1.	(a) Whether your entity’s policy/ policies cover each	Yes	Yes Yes Yes Yes Yes	Yes	Yes	Yes
	principle and its core elements of the NGRBCs. (Yes/
	No) *
The Company has adopted, to the extent applicable, “The Blue		Book -	Summary of Pfizer Policies on Business Conduct” of its		parent Company,
Pfizer Inc., USA. The Blue Book along with the Company’s local		policies cover all the above 9 principles.
	(b) Has the policy been approved by the Board? (Yes/No)	Yes	Yes Yes Yes Yes Yes	Yes	Yes	Yes
The Board of Directors of the Company has adopted, to the extent applicable “The Blue Book - Summary of Pfizer Policies on Business Conduct”
of Pfizer Inc., its parent company.
	(c) Web Link of the policies, if available	https://www.pfizerltd.co.in/files/pfizerincbluebook.pdf
2.	Whether the entity has translated the policy into	Yes	Yes Yes Yes Yes Yes	Yes	Yes	Yes
	procedures? (Yes/No)
3.	Do the enlisted policies extend to your value chain	Yes	Yes Yes Yes Yes Yes	Yes	Yes	Yes
	partners? (Yes/No)
4.	Name of the national and international codes/	•	The Company’s Goa manufacturing facility is	WHO (World Health
	certifications/labels/standards (e.g., Forest Stewardship		Organization) and GMP (Good Manufacturing Practices) certified.
	Council, Fairtrade, Rainforest Alliance, Trustea) standards	•	As a member of Organization of Pharmaceutical Producers of			India,
	(e.g., SA 8000, OHSAS, ISO, BIS) adopted by your entity		the Company follows a robust code of conduct on ethical marketing
	and mapped to each principle.		practices for pharmaceutical companies.

The Company is compliant with the “Uniform Code for Pharmaceutical Marketing Practices (UCPMP).

Disclosure Questions	Disclosure Questions	P1 P2 P3 P4 P5 P6 P7 P8 P9
5.	Specific commitments, goals, and targets set by the	Our parent company, Pfizer Inc., has voluntarily committed to achieve Net
	entity with defined timelines if any.	Zero standard by 2040.
		The Company, as a subsidiary of Pfizer Inc., is adopting measures in line with
		Pfizer Inc.’s goal to achieve the voluntary Net Zero Standard by 2040. The
		Company at its Manufacturing plant at Goa, expanded its PV Solar Project
		to 1,500 kWp leading to 53% reduction in conventional power consumption
		in FY 2024-25 over the previous year. Several other initiatives such as Energy
		efficiency, Zero Liquid Discharge (ZLD), Waste management initiatives, etc.
		were undertaken by the Company during the financial year under review.
		For further details, please refer to Pfizer Inc.Impact Report 2024:https://cdn.
		pfizer.com/pfizercom/Pfizer_2024_Impact_Report_02JUN2025.pdf
6.	Performance of the entity against the specific	Pfizer is a global biopharmaceutical company focused on advancing our
	commitments, goals, and targets along with reasons in	Purpose—Breakthroughs That Change Patients’ Lives with an ambition to
	case the same are not met.	change a billion lives a year by 2027. Pfizer Limited, being a subsidiary of Pfizer
		Inc., is aligned to its parent company’s vision, mission, and core values—
		Courage, Excellence, Equity, and Joy. Our progress on responsible business
		growth space is strong and on track as per our commitment; we are taking
		initiatives, programs, and activities in line with our global commitments to
		ensure continuous process improvements and solutions for quality delivery.

Governance, leadership, and oversight

Statement by the director responsible for the business responsibility report, highlighting ESG related challenges, targets, and achievements (listed entity has flexibility regarding the placement of this disclosure)

At Pfizer Limited, we are mindful of the impact a Company of our size and scale has on the planet and are working continuously to assure that it is a positive one in every aspect. Pfizer is committed towards creating a more sustainable future for all. We recognize that we are operating in an ever-changing world, and that our stakeholders expect us to step up and act against threats to human health & well-being and also, the overall health of our planet. We have an obligation to utilize our resources to help solve such problems - whether from extreme weather events caused by climate change, social unrest, inequality, or any other external factors. Globally, Pfizer’s track record in the responsible business growth space is strong, and we look forward to continuing to build on it.

Discovering, manufacturing, and delivering innovative medicines is only a part of what we contribute to society.

We proactively act and collaborate in advancing our priorities related to responsible business growth. We aim to continuously improve health outcomes, build trust, create shared value, and positively impact the society for years to come and take care of the future generations. We focus on the following six priority areas:

i. Product Innovation: Reducing cycle times, increasing success rates, and getting more breakthroughs into the hands of patients sooner.
ii. Equitable Access and Pricing: Expanding affordable access to our breakthrough medicines, vaccines, and protecting people from the burden of infectious and other diseases.
iii. Product Quality and Safety: Maintaining a quality culture to ensure the highest priority is placed on the safety, efficacy, and reliability of our products, the safety of our patients and consumers, the quality of data supporting regulatory submissions, and interactions with our stakeholders.
iv. Business Ethics: Exercising strong corporate governance and risk management practices to promote the long-term interests of our stakeholders.
v. Diversity, Equity, and Inclusion: Creating opportunities to advance merit-based diversity, equity, and inclusion across our workforce, those with whom we do business, and society at large.
vi. Climate Change: Taking action to reduce our greenhouse gas emissions and mitigate risks associated with a changing climate.

In our quest to enhance sustainability performance, we are deepening partnerships with key stakeholders, including contractors, suppliers, and customers, fostering a collective culture of sustainability across the value chain. We are also committed to support and encourage the wellness of our colleagues through multiple breakthrough benefits and wellbeing initiatives. Our governance policies, aligned with Pfizer Inc.’s ESG priorities, guide us in managing ESG risks and seizing new opportunities. We sincerely thank our stakeholders for their steadfast support and confidence in our sustainability efforts. Together, we will drive transformation and work towards a brighter future for a healthier planet.

Disclosure Questions	Disclosure Questions	P3	P4	P6 P7
8.	Details of the highest authority responsible for implementation and oversight	of the	Business	Mr. P. Rengan
	Responsibility policy (ies)			Executive Director - Plant
				Operations
				DIN: 10362899
9.	Does the entity have a specified Committee of the Board/ Director responsible	for decision making on		No.
	sustainability related issues? (Yes/No).			Please refer to details mentioned
	If “Yes”, provide details			in point 8 above.

Details of Review of NGRBCs by the Company:

Indicate whether review was undertaken by Frequency (Annually/ Half yearly/ Quarterly/ Director/ Committee of the Board/ Any other Subject for Review Committee Any Other- please specify) P1 P2 P3 P4 P5 P6 P7 P8 P9 P1 P2 P3 P4 P5 P6 P7 P8 P9 Performance against Quarterly by the Audit Committee above policies and follow up action Compliance with Yes, the Company is compliant with all applicable Quarterly by the Board of Directors statutory requirements regulations, laws and statutory requirements of relevance to which are regularly tracked, monitored, and the principles, and reviewed periodically by the Management and rectification of any nonby the highest governance body i.e., Board of compliances Directors.

Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No).

If “Yes”, provide name of the agency.

P1 P2 P3 P4 P5 P6 P7 P8 P9

The Company periodically reviews the working of the Policies and refresher training is provided to the employees, while no formal evaluation of the policies is carried out by an external agency. However, Certain policies are reviewed by the Company’s internal auditors and secretarial auditors within the scope of their respective audits, as deemed necessary.

If Answer to Question (1) Above is “NO”, i.e., not all Principles are covered by a Policy,	If Answer to Question (1) Above is “NO”, i.e., not all Principles are covered by a Policy,	If Answer to Question (1) Above is “NO”, i.e., not all Principles are covered by a Policy,	reasons	to be stated:	to be stated:
Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business
(Yes/No)
The entity is not at a stage where it is in a position to formulate
and implement thepolicies on specifiedprinciples (Yes/No)
The entity does not have the financial or human and technical				Not Applicable
resources available for the task (Yes/No)
It isplanned to be done in the next financialyear (Yes/No)
Any Other Reason (please specify)

Section C: Principle Wise Performance Disclosure

Entity demonstrates their performance in integrating the Principles and Core Elements with key processes and decisions.

Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent, and Accountable

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year 2024-25:

2024-25:
Segment	Total number	Topics/ Principles covered under training and its impact	Percentage
	of training and		age of persons
	awareness		in respective
	programs held		category covered
			by the awareness
			programmes
Board of	25	The Company has put in place a familiarization program	100%
Directors		for its Board of Directors (‘BOD’) which covers topics
		such as overview of the pharmaceutical market, industry
		performance, updates on business and growth strategy,
		regulatory changes, etc.
		The BOD is regularly updated with the Company’s policies
		on integrity, ethics, transparency & accountability at
		regular intervals.
		Comprehensive induction programs were conducted to
		familiarize the newly appointed Independent Directors
		with the Company’s Business, Strategies and Policies.
		The BOD is also made aware of the Company’s Risk
		Management framework, Compliance framework and
		Internal control framework.
Key	90	Colleague receives role-specific trainings on our Code of	100%
Managerial		Conduct and other key areas, including ethical standards,
Personnel		anti-bribery / anti-corruption training upon hiring and
Employees other than		regularly thereafter (normally every one to two years), to reinforce our policies and commitment to integrity.
BoD and		Our ethics and compliance training programs use multi-
KMPs		modal components and are designed to address different
Workers		learning styles, maximize engagement, and reinforce training content. Our training program encompasses role-
		based scope of topics and depth of knowledge to help
		drive training effectiveness. Curated training programs
		covering wide gamut across all principles including topics
		such as (but not limited to) Code of Conduct, Prevention
		of Sexual Harassment (“POSH”), skill upgradation, health
		safety and environment etc., are mandatorily required
		to be completed by all employees including KMPs and
		workers.
		The Company also conducts various awareness programs
		related to health and well-being of the employees and
		workers.
		Additionally, trainings are also conducted for Trade
		Secret Role, Anti-Bribery and Anti-Corruption, Get Access
		Sponsor/Delegate, Interactions with Patients and Patient
		AdvocacyGroups and PGS GMP/GDP QualityManual.

2. Details of fines/ penalties/ punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors/ KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format:

(Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as discussed on the entity’s website)

		Monetary
	NGRBC	Name of the Regulatory/	Amount	Brief of Case	Has an appeal
	Principle	enforcement agencies/	(in`)		been preferred?
		judicial institutions			(yes/ No)
Penalty/ Fine	–	–	–	–	–
Settlement	–	–	–	–	–
Compounding Fee	–	–	–	–	–

		Non-Monetary
	NGRBC	Name of the Regulatory/ enforcement		Brief of Case	Has an appeal
	Principle	agencies/ judicial institutions			been preferred?
					(yes/ No)
Imprisonment	–	–		–	–
Punishment	–	–		–	–

3. Of the instances disclosed in Question 2, above detail of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
	Not applicable.

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide web-link to the policy.

Yes, the Company’s anti bribery policy prohibits all forms of bribery and corruption, whether by colleagues or its business partners. Colleagues and business partners must never offer, promise, authorize, or provide a payment or benefit that is intended to improperly influence a government official, healthcare professional, or any other person, including commercial entities and individuals, in exercising their responsibilities.

The Company is guided, to the extent applicable, by the “Blue Book - Summary of Pfizer Policies on Business Conduct” — of its parent company, Pfizer Inc., USA. Pfizer’s Blue Book—our Code of Conduct—is designed to support our core Values, particularly Excellence, as we perform at our best together, and Equity, as we should always act with integrity. The Blue Book describes how we operate and guides the decisions we make in support of our purpose, including how we speak up when we see something that concerns us—a behavior essential to our Value of Courage. Seeking advice, raising concerns, and reporting misconduct are critical to our ability to serve patients. Every Pfizer colleague is responsible for understanding the Blue Book and adhering to our Code of Conduct every day. In doing so we demonstrate our continued commitment to living our Values and earning the trust of the patients we serve.

In addition to this, Pfizer’s My Anti-Corruption Policy, and Procedures (“MAPP”) sets out Pfizer’s global enterprise-wide approach to preventing bribery and corruption. MAPP provides the tools needed to help address bribery and corruption risks in our interactions with healthcare professionals, government, regulators, and business partners. By following MAPP and acting in accordance with applicable laws and Pfizer’s values, each Pfizer colleague contributes to our culture of ethics and integrity. Further to our prohibition of all forms of bribery, we are committed to fostering a culture of ethics and integrity and committed to competing lawfully and ethically in the marketplace and expect every Pfizer Colleague and business partner to conduct all aspects of Pfizer business with integrity. Resources, training, and messaging emphasize the accountability of leaders to own compliance and engage in proactive risk management and ethical decision-making and to make clear that non-compliant conduct is not tolerated. Pfizer also strives to be an ethical leader within our industry by taking leading roles within industry associations and diverse business forums to advance anti-corruption efforts. The policies can be accessed via following web links:

https://www.pfizerltd.co.in/files/Pfizer_2023BlueBook.pdf https://www.pfizer.com/about/responsibility/compliance/anti-bribery-and-anti-corruption https://cdn.pfizer.com/pfizercom/MAPP_Summary_2022_Updated.pdf

5. Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:

Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:	Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:	Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:
Current Financial Year 2024-25 Previous Financial Year 2023-24
Directors	–	–
Key Managerial Personnel (KMPs)	–	–
Employees	–	–
Workers	–	–

6. Details of complaints with regard to conflict of interest:

	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24
	Number Remark Number Remark
Number of complaints received in relation to issues of Conflict of Interest of the Directors	–	–	– –
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	–	–	– –

7. Provide details of any corrective action taken or underway on issues related to fines/ penalties/ action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Not Applicable, as there were no cases of non-compliance in the Company during the reporting year.

8. Number of days of accounts payables ((Accounts payable*365)/ Cost of goods/services procured) in the following format:

*Number of days of accounts payables ((Accounts payable365)/ Cost of goods/services procured) in the following format:**	*Number of days of accounts payables ((Accounts payable365)/ Cost of goods/services procured) in the following format:**	*Number of days of accounts payables ((Accounts payable365)/ Cost of goods/services procured) in the following format:**
Current Financial Year 2024-25 Previous Financial Year 2023-24
Number of days of accountspayables	49	59

9. Openness of Business:

Provide details of concentration of concentration of purchases and sales with trading houses, dealers, and related parties along with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics Current Financial Year 2024-25 Previous Financial Year 2023-24	Metrics Current Financial Year 2024-25 Previous Financial Year 2023-24	Metrics Current Financial Year 2024-25 Previous Financial Year 2023-24
Concentration of Purchases	a. Purchases from trading houses as % of the total purchases	–	–
	b. Number of trading houses where purchases are made from	–	–
	c. Purchases from top 10 trading houses as % of totalpurchases from tradinghouses	–	–
Concentration of Sales	a. Sales to dealers/ distributors as % of total sales	98.68%	98.79%
	b. Number of dealers/ distributors to whom sales are made	5,097	5,283
	c. Sales to top 10 dealers/ distributors as % of total sales to dealers/ distributors	33.68%	35.39%
Share of RPTs in	a. Purchases (Purchases with related parties/ Total Purchases)	66.06%	56.41%
	b. Sales(Sales to relatedparties/ Total Sales)	–	–
	c. Loans & advances (Loans & advances given to relatedparties/ Total loans & advances)	–	–
	d. Investments (Investments in related parties/ Total Investments made)	–	–

Leadership Indicators

1. Awareness programmes conducted for the value chain partners on any of the Principles during the financial year 2024-25:

Total number	Topics/ Principles covered under the training	Topics/ Principles covered under the training	Percentage of value chain
of awareness			partners covered (by value of
programmes			business done with such partners)
held			under the awareness programmes
3	Knowledge sharing and awareness cum sessions were
	undertaken for its vendors and suppliers during the year,
	covering topics like:
	a)	Stockiest Supply Chain Awareness Program under
		Umang: Commercial meet with top 100 customers
		to discuss and deliberate on future plans of business
		expansion with their support and appreciate top
		ordering customers with recognition.
	b)	Training on Pfizer issued laptops to value chain
		partners and logistics service providers to have
		seamless communication and data sharing
		knowledge.
	c)	The migration from SAP ECC to S4 Hana was a
		critical project necessitating thorough planning and
		execution. A fundamental aspect of this transition	100%
		involved ensuring that both internal and external
		users were suitably trained and prepared for the
		changes. The Company rolled out a training program
		which was customized to address the specific needs
		of all users, with a particular emphasis on seamless
		transition and operational continuity.
		The Company commenced a series of communications
		six months prior to the migration, highlighting
		key resources and information about the S4 Hana
		system. One month before the migration, we
		conducted multiple calls to clarify the do’s and don’ts
		before, during, and after the blackout period. These
		calls ensured that all transactions and integrations
		to multiple gateways remained intact and functioned
		correctly.

2. Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No).

If “Yes”, provide details of the same.

Pfizer Limited is dedicated to operating its business in accordance with ethical standards and in compliance with all relevant laws and regulations. This dedication is demonstrated by following our Code of Conduct, which applies to every member of the Board of Directors. Every Director is expected to comply, in letter and spirit, with all laws applicable to his / her service as a ‘Director’. If Director discloses his / her interest, direct or indirect, in other companies or entities (either as a Director, Shareholder or otherwise) under section 184 of Companies Act, 2013 that will be deemed to be sufficient compliance with this Code. The Code is available at: https://www.pfizerltd.co.in/model-code.

Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe.

Essential Indicators

1. Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.

ciple 2: Businesses should provide goods and services in a manner that is sustainable and . ntial Indicators Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.	ciple 2: Businesses should provide goods and services in a manner that is sustainable and . ntial Indicators Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.	ciple 2: Businesses should provide goods and services in a manner that is sustainable and . ntial Indicators Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.
Current Financial Year 2024-25 Previous Financial Year 2023-24 Details of improvements in environmental and social impacts
R&D	–	– –
Capex	20%	18.90% The capital expenditure includes expenses incurred towards improving production efficiency thereby reducing energy consumption at the Company’s Goa site which helps in reduction of Greenhouse Gas (“GHG”) emissions.

2. a. Does the entity have procedures in place for sustainable sourcing? (Yes/No).

b. If “Yes”, what percentage of inputs were sourced sustainability?

Yes. The Company, through its parent company Pfizer Inc., has procedures in place designed to help ensure third party partners for materials and services meet our standards, i.e., select suppliers that are responsible, ethical, and reliable partners. After the suppliers are selected and onboarded, they are required to comply with Pfizer’s Responsible Sourcing guidelines and Supplier Conduct Principles, which are aligned to the Pharmaceutical Supply Chain Initiative (PSCI) Principles for Responsible Supply Chain Management. Pfizer Inc.’s regular evaluation of external partners extends to assessing environmental, health, safety, and sustainability performance, including labour and human rights reviews. Our collaborations with our suppliers are focused on improving sustainability, compliance with laws, and alignment to our Supplier Conduct Principles and the PSCI Principles for Responsible Supply Chain Management.

The Company monitors the performance of and regularly audits its key material suppliers. Audit outcomes are used to drive continuous improvement in both performance and compliance. At Pfizer, we require our suppliers to develop action plans in response to our audits and implement improved controls, as needed. The Company undertakes initiatives through PSCI partnership programs to educate its suppliers through webinars and conferences on the PSCI principles to build capacity of its business partners to adhere to responsible and sustainable procurement practices.

88.8% of Active Pharmaceutical Ingredients used in manufacturing at the Goa Plant and Contract Manufacturing sites are sourced sustainably.

Web-link to Responsible Sourcing Guidelines: https://www.pfizer.com/about/partners/B2B-and-suppliers/ - responsible sourcing

3. Describe the processes in place to safely reclaim your products for reusing, recycling, and disposing at the end of life for:

a. Plastics (including packaging)
b. E-waste
c. Hazardous waste
d. Other waste

The Company’s purpose—Breakthroughs that change patients’ lives—guides its environmental priorities, with a focus on impact reduction, conservation of resources, and the minimization of waste arising from operations. We are committed to reducing our environmental footprint, conserving resources, and reducing waste arising from our operations. The Company’s sites consistently seek opportunities to reduce, reuse, repurpose and recycle materials such as packaging and plastics.

The Company’s manufacturing unit has robust waste management systems in compliance with regulatory requirements and the Company’s internal Environment, Health, and Safety (“EHS”) standards.

All the waste generated within the manufacturing and office premises is segregated into hazardous waste, nonhazardous waste, e-waste, and plastic waste which are disposed/recycled in accordance with the regulatory requirements. Plastic waste generated from the operations is disposed in accordance with the applicable laws. The Company is eligible for Extended Producer Responsibility (“EPR”) and has submitted its EPR plan for plastic waste management to the Central Pollution Control Board.

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes/No).

If “Yes”, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Board?
If “Not”, provide steps taken to address the same.

Yes, EPR is applicable to the Company’s activities and the Company handles, processes, and disposes plastic waste in line with the EPR plan submitted to the Central Pollution Control Board under the category of “Brand Owner”.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective/ Assessment (LCA) for any of its products (for manufacturing industries) or for its services (for service industry)? If “Yes”, provide details in the following format:

Name of	% of Total	Boundary for	Whether	Results communicated
product/ service	Turnover	which the Life	conducted by	in public domain
	contributed	cycle perspective/	independent	(Yes/No)
		assessment was	external agency	If “Yes”, provide
		conducted	(Yes/No)	web-link

Pfizer Limited has not undertaken Life Cycle Assessment (LCA) during the reporting period.

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products/ services, as identified in the Life Cycle Perspective/ Assessments (LCA) or through any other means, briefly describe the same along with action-taken to mitigate the same.

Name of Product/	Description of	the risk/ concern	the risk/ concern			Action Taken
Service
Pharmaceutical	Hazardous	waste	generated		during	All hazardous wastes are collected safely
Products	manufacturing		process,	negatively		and sent for incineration, as per applicable
	impacting environment and human health,					regulations under supervision.
	if not managed and		disposed efficiently and
	scientifically.
Pharmaceutical	Plastic waste	generated at the end-of-life of				Plastic waste generated from products
Products	the product i.e., post consumption, leading					through distribution is taken back equivalently
	to increased dump of plastics at landfills.					through different means, in accordance with
						the Extended Producer Responsibility (“EPR”)
						plan submitted by Pfizer Limited for plastic
						waste to the Central Pollution Control Board.
						The Company has partnered with authorized
						recycler to meet its EPR obligations and ensures
						to meet its said target within the timelines to
						minimize the negative impact of plastic waste
						on human health and environment.

3. Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).

Indicate input material	Recycled or re-used input material to total material
	Current Financial Year 2024-25 Previous Financial Year 2023-24
	Not applicable.

4. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:

==> picture [455 x 39] intentionally omitted <==

----- Start of picture text -----

Current Financial Year 2024-25 Previous Financial Year 2023-24
Re-Used Recycled Safely Re-Used Recycled Safely
Disposed Disposed
----- End of picture text -----


Plastics (including packaging)	–	1,623	–	– 1,323 –
E-Waste	N.A.	N.A.	N.A.	N.A. N.A. N.A.
Hazardous Waste	N.A.	N.A.	N.A.	N.A. N.A. N.A.
Other Waste	N.A.	N.A.	N.A.	N.A. N.A. N.A.

5. Reclaimed products sand their packaging materials (as percentage of products sold) for each product category

category
Indicate Product Category	Reclaimed products and their packaging materials as %
	total products sold in respective category
	Not applicable.

Principle 3: Businesses should respect and promote the well-being of all employees, including those in their value chains.

Essential Indicators

1. a. Details of measures for the well-being of Employees:

Category Total (A)	Health Insurance Accident Insurance Maternity Benefits Paternity Benefits Day Care Facilities
	Number (B) % (B/A) Number (C) % (C/A) Number (D) % (D/A) Number (E) % (E/A) Number (F) % (F/A)
	Permanent Employees
Male 1,316	1,316 100% 1,316 100% – – 1,316 100% – –
Female 247	247 100% 247 100% 247 100% – – 216 87%
Total 1,563	1,563 100% 1,563 100% 247 100% 1,316 100% 216 87%
	Other than Permanent Employees
Male 80	77 91% 77 91% – – 32 40% – –
Female 90	77 86% 77 86% 77 86% – – – –
Total 170	154 91% 154 91% 77 86% 32 40% – –

*: The Company has 16 Individual Consultants, and it does not provide any Health Insurance, Accident Insurance, Maternity Benefits, Paternity Benefits and Day Care Facilities to them.

1. b. Details of measures for the well-being of Workers:

Category Total (A)	Health Insurance Accident Insurance Maternity Benefits Paternity Benefits Day Care Facilities
	Number (B) % (B/A) Number (C) % (C/A) Number (D) % (D/A) Number (E) % (E/A) Number (F) % (F/A)
	Permanent Workers
Male 35	35 100% 35 100% – – 35 100% – –
Female –	– – – – – – – – – –
Total 35	35 100% 35 100% – – 35 100% – –
	Other than Permanent Workers
Male –	– – – – – – – – – –
Female –	– – – – – – – – – –
Total –	– – – – – – – – – –

1. c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format

Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format	Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format	Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format
Current Financial Year 2024-25 Previous Financial Year 2023-24
Cost incurred on well-being measures as a % of total revenue of the Company	0.37%	0.41%

2. Details of retirement benefits, for Current FY 2023- 24 and Previous FY 2022- 23

Benefits	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24
	No. of employees covered as % of total employees No. of workers covered as % of total workers Deducted and Deposited with the authority (Yes/ No/ NA) No. of employees covered as % of total employees No. of workers covered as % of total workers Deducted and Deposited with the authority (Yes/ No/ NA)
PF	100%	100%	Yes	100% 100% Yes
Gratuity	100%	100%	NA	100% 100% NA
ESI	100%	100%	Yes	100% 100% Yes
Others- Superannuation	1.43%	–	–	1.72%^ – –

ESI benefit is extended to all eligible employees.

Note: The Provident Fund, Gratuity and Superannuation contributions are deposited with the Company’s respective Trust Funds / EPFO.

^In FY 2023-24, certain colleagues have been re-grouped, hence the deviation in percentage.

3. Accessibility of Workplaces

Are the premises/ offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

If “Not”, then whether any steps are being taken by the entity in this regard.

Yes. Following arrangements are provided at the Company’s premises: Dedicated parking, security support, disabled-friendly washrooms, adequate space for wheelchair movement, visual and audio alarms, emergency evacuation chair, ramps in the basement at entry points, etc. The Company continues to work towards identifying the needs of employees with disabilities and proactively supporting them.

Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, please provide the web-link of the policy.

Yes, the Company has “Equal Employment Opportunity Policy” in line with the Rights of Persons with Disabilities Act, 2016 for persons with physical or mental disabilities; accessible at Web-link: https://www.pfizerltd.co.in/ files/pfizerincbluebook.pdf

Return to work and Retention rates of permanent employees and workers that took parental leave for FY 2024-25.

Gender	Permanent Employees Permanent Workers
	Return to Work Rate Retention Rate Return to Work Rate Retention Rate
Male	100% 100% 100% 100%
Female	100% 100% 100% 100%
Total	100% 100% 100% 100%

6. Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If “Yes”, give details of the mechanism in brief:

Permanent Workers Yes. Other than Permanent Workers Pfizer recognizes the critical importance and value of Pfizer’s employees Permanent Employees and the need to build and sustain a culture where all employees can Other than Permanent Employees contribute their unique viewpoints and perspectives to all aspects of the business. Courage is a core value, and we promote a speak up environment. Our whistleblowing policies (e.g., Open Door policy) and strict anti-retaliation policies require reporting misconduct and encourage raising concerns about any issues. Retaliation against anyone who seeks advice, raises a concern, reports misconduct, or provides information in an investigation is prohibited.

The Company takes all policy concerns seriously and, to the extent violations of policy are identified, takes appropriate disciplinary action and corrective actions, including potential termination. We measure our culture of integrity with surveys, and the results are used to focus leadership communications, training, and other proactive improvement efforts. We provide multiple channels for asking questions and raising potential compliance concerns, including anonymous reporting options were permitted by law, and keep matters as confidential as possible.

The avenues for raising concerns are listed in the Blue Book and on our website www.pfizerltd.co.in, both of which are publicly available. Every employee, irrespective of hierarchy, has access to the Employee Relations Investigations Group, Compliance or Legal Division, Ombuds Office, People Experience Division of the Company and in appropriate and exceptional cases, concerns may be raised directly to the Chairman of the Audit Committee of the Company.

7. Membership of employees and workers in association(s) or Unions recognized by the listed entity:

Benefits	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24
	Total employees/ workers in respective category (A) No. of employees/ workers in respective category, who are part of Association(s) or Unions(B) Percentage (%) (B/A) Total employees/ workers in respective category (A) No. of employees/ workers in respective category, who are part of Association(s) or Unions(B) Percentage (%) (B/A)
Total Permanent Employees	1,563	29	1.86%	1,685 36 2.14%
- Male	1,316	28	2.13%	1,382 35 2.60%
- Female	247	1	0.40%	303 1 0.33%
Total Permanent Workers	35	35	100%	36 36 100%
- Male	35	35	100%	36 36 100%
- Female	0	0	0%	0 0 0%

8. (a). Details of training given to employees and workers on “Health and Safety Measures”

==> picture [456 x 38] intentionally omitted <==

----- Start of picture text -----

Category Current Financial Year 2024-25 Previous Financial Year 2023-24
Total Number Percentage Total Number Percentage
(A) (B) (%) (B/A) (C) (D) (%) (D/C)
----- End of picture text -----

	Total (A)	Number (B)	Percentage (%) (B/A)	Total (C) Number (D) Percentage (%) (D/C)
		E	mployees
Male	1,316	1,316	100%	1,382 1,382 100%
Female	247	247	100%	303 303 100%
Total	1,563	1,563	100%	1,685 1,685 100%
			Workers
Male	35	35	100%	36 36 100%
Female	0	0	100%	0 0 100%
Total	35	35	100%	36 36 100%

*: The Company has 16 Individual Consultants, and it does not provide any Health Insurance, Accident Insurance, Maternity Benefits, Paternity Benefits and Day Care Facilities to them.

(b). Details of training given to employees and workers on “Skill Upgradation”

==> picture [455 x 37] intentionally omitted <==

	Total (A)	Number (B)	Percentage (%) (B/A)	Total (C) Number (D) Percentage (%) (D/C)
		E	mployees
Male	1,316	1,316	100%	1,382 1,382 100%
Female	247	247	100%	303 303 100%
Total	1,563	1,563	100%	1,685 1,685 100%
			Workers
Male	35	35	100%	36 36 100%
Female	0	0	100%	0 0 100%
Total	35	35	100%	36 36 100%

The Company conducts regular health and safety training sessions for all its permanent employees. The sessions on Skill Upgradation cover a range of skill upgrades, encompassing both soft skills and functional expertise. Additionally, individual departments offer training tailored to their specific requirements, although these are not separately monitored or tracked.

Note: In FY 2023-24 certain colleagues have been re-grouped.

Data is for ‘Permanent Employees and Workers’ for FY 2023-24 and FY 2024-25.

9. Details of Performance and Career Development reviews of employees and workers:

==> picture [456 x 38] intentionally omitted <==

	Total (A)	Number (B)	Percentage (%) (B/A)	Total (C) Number (D) Percentage (%) (D/C)
		E	mployees
Male	1,316	1,316	100%	1,382 1,382 100%
Female	247	247	100%	303 303 100%
Total	1,563	1,563	100%	1,685 1,685 100%
			Workers
Male	35	35	100%	36 36 100%
Female	0	0	100%	0 0 100%
Total	35	35	100%	36 36 100%

Note: In FY 2023-24 certain colleagues have been re-grouped.

Performance review and career development appraisal is carried out half yearly for permanent employees.

Data is for ‘Permanent Employees and Workers’ for FY 2023-24 and FY 2024-25.

10. Heath and Safety Management System:

a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/No)
If “Yes”, then coverage of the system.
b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis of the entity?

Yes, the Company has an occupational health and safety management system in place based on Pfizer Global EHS standards. The Global EHS Policy and supporting standards outline Pfizer’s approach to assessment, evaluation, elimination, and mitigation of EHS risks across its operations globally. In addition, they facilitate colleague engagement in EHS thereby enabling continuous improvement. Each Pfizer colleague and contingent worker plays a crucial role in facilitating a culture of EHS excellence where improvements, ideas, suggestions, and opportunities are welcomed. Fostering this culture of interdependence with everyone looking out for each other enables Pfizer to meet its commitment to its patients. The said system covers the Company’s plant, head office, regional offices and all employees and workers based in those locations. Periodic internal and cross-site audits are conducted to improve the Company’s EHS practices and reduce workplace hazards.’

The Company uses Hazard Identification and Risk Assessment (“HIRA”) for routine and non-routine activities to identify and mitigate all current and reasonably foreseeable hazards. Further, the Company undertakes periodic audits, evaluations of emergency and crisis response plans and mock drills to help identify and assess work related hazards. With a view to provide a safe and healthy work environment to its employees and workers, risk assessment is part of employees’ and workers’ online training program wherein the risk profile of each employee or worker is evaluated following which positive reinforcing conversations are held with the respective employee or worker. In addition, the Company launched a focused program on Serious Injury and Fatality Prevention designed to increase hazard awareness and drive a more proactive approach to injury prevention. Further, the India Driver Safety program of the Company focuses on reducing the risk associated with driving. Further, the Company has systems in place for assessing ergonomic, occupational, process safety hazards and risks.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks? (Yes/No)
d. Do the employees/ workers of the entity have access to nonoccupational medical and healthcare services? (Yes/No)
Yes, the Company has established an internal mechanism to facilitate reporting of hazards at the workplace. The Company’s leaders set the tone for our strong culture of acting with integrity in all we do and support a speak-up culture in which all workers can raise concerns without fear of retaliation. Measures are subsequently taken to investigate and mitigate these hazards. The Company has established an internal EHS Committee that periodically reviews the mitigation steps taken.
Yes, all employees and workers are covered under Company’s health insurance and accident policy.

11. Details of safety related incidents, in the following format:

Safety Incidents/ Number	Category Current Financial Year 2024-25 Previous Financial Year 2023-24	Category Current Financial Year 2024-25 Previous Financial Year 2023-24	Category Current Financial Year 2024-25 Previous Financial Year 2023-24
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	–	–
	Workers	–	–
Total recordable work-related injuries	Employees	–	–
	Workers	–	–
Number of fatalities	Employees	1*	–
	Workers	–	–
High consequence work-related injury or ill– health(excluding fatalities)	Employees	–	–
	Workers	–	–

*Fatality due to road accident during field work.

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

The foundation of Pfizer’s EHS program is robust EHS management systems. Pfizer Inc.’s EHS programs, applicable to all operations globally including the Company’s operations, and place an emphasis on identifying and managing EHS risk. The programs are described within Global EHS Standards structured very similarly to the ISO 14001 framework with implementation at all sites verified through the Pfizer internal EHS audit program. At the Company level, EHS governance is overseen by the Company’s internal EHS Committee that involves representation from all levels of the organization. EHS performance is regularly reviewed to help ensure high standards of conduct. The Company has a robust health and safety management system based on its internal standards which are aligned with applicable standards for occupational health and safety. The Company uses EHS risk assessment as a business planning tool to proactively design and manage operations, thereby mitigating risk and preventing harm. Further EHS governance is subject to multiple audits at local and global level. The Company has systematic processes for continued evaluation of risks and implementation of mitigation. Employees are given periodic training to equip themselves to work in a safe manner. The Company has a wellness center that offers primary medical services including medical emergencies. The Company also conducts wellness sessions as part of the wellness center program. The Company also has a detailed emergency and crisis response plan for manufacturing site and office locations, and periodic mock drills are conducted to familiarize the employees for any imminent risks.

13. Number of complaints on the following made by employees and workers:

	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24
	Filed Pending Resolution at end of year Remark Filed Pending Resolution at end of year Remark
Working Conditions	– – –	– – –
Health and Safety	– – –	– – –

14. Assessment for the Year (2024-25):

Health and Safety – Assessment for the Year (2024-25):	– – – – –
	% of plants and offices that were assessed
	(by entity or statutory authorities or third party)
Health and Safety Practices	100%*
Working Conditions	100%#

The Company conducts regular self-assessments for its Plant and Office facilities to help ensure compliance with applicable health and safety requirements. Pfizer conducts regular internal audits of all facilities.

The Company conducts assessments based on regulatory requirements, if applicable, and the Company’s Internal Policies. Environmental working conditions in terms of air quality, noise etc. are monitored pursuant to applicable regulatory requirements. The Company conducts regular self-assessments for its Plant and Office facilities to help ensure compliance with applicable environmental requirements. The Company also conducts regular internal audits of all facilities.

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risk/ concerns arising from assessment of health and safety practices and working conditions.

No Significant risks / concerns were identified during the reporting period. The Company had two minor findings during an internal Level II EHS Audit and the same were being remediated as part of the health and safety improvement plan.

Leadership Indicators

1. Does the entity extend any life insurance or compensatory package in the event of death of (A). Employees; and (B). Workers (Yes/No). Provide detail.

Yes, the Company covers all its employees under its Group Personal Accident and Group Term Life Insurance Policy. In addition, the Company provides compensatory package in the event of death of an employee or worker.

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

Pfizer Limited works to ensure that statutory dues have been deducted and deposited by the value chain partners. When it comes to statutory requirements that involve licenses (FSSAI, DL, S&E), value chain partners, along with Global Supply Chain team, maintain a tracker and repository of all documents. The requirements pertaining to payment of statutory dues for sub-contracted manpower, forms part of the agreements entered between the Company and the value chain partners. Compliance of payment of said dues are reviewed and confirmed and during internal audits as well.

3. Provide the number of employees/ workers having suffered high consequence work-related injury/ illhealth/ fatalities (as reported in Qs. 11 of Essential Indicators above), who have been/ are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total Number of affected employees/ workers No. of employees/ workers that are rehabilitated or whose family member have been placed in suitable employment	Total Number of affected employees/ workers No. of employees/ workers that are rehabilitated or whose family member have been placed in suitable employment	Total Number of affected employees/ workers No. of employees/ workers that are rehabilitated or whose family member have been placed in suitable employment	Total Number of affected employees/ workers No. of employees/ workers that are rehabilitated or whose family member have been placed in suitable employment
	FY 2024-25 FY 2023-24 FY 2024-25 FY 2023-24
Employees	1	–	–	–
Workers	–	–	–	–

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/No)

The Company provides support to all its employees and workers in the form of training and capacity building, even at the verge of retirement period through a third-party vendor. In case of termination of employment, a career transition fee is provided to support their transition to new sectors or job roles. This fee help cover the costs of training and acquiring industry-relevant skills, making it easier for employees to pivot and improve their employability.

5. Details on assessment of value chain partners (FY 2024-25):

	% of value chain partners (by value of business done
	with suchpartners) that were assessed
Health and Safety Practices	100%
Working Conditions	100%

6. Provide details of any corrective actions taken or underway to address significant risks/ concerns arising from assessments of health and safety practices and working conditions of value chain partners.

The Company has set high standards for responsible supply chain management, guided by robust governance processes. This helps ensure the safety and quality of the medicines and vaccines we market and aligns with our core value of Equity.

The Company has annual market excellence assessments covering Risk and Compliance parameters like EHS, BCP with our value partners. Along with the same, we conduct quarterly virtual audits where standard parameters like statutory compliances, storage compliances and governance, safety, security, sustainability, and inventory management are audited.

Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders. Essential Indicators

1. Describe the process for identifying key stakeholder groups of the entity.

Throughout the organization, we maintain regular engagement with diverse stakeholders, encompassing employees, shareholders / investors, value chain partners, suppliers, Government, industry associations, nonprofit organizations, and communities. We identify key stakeholder groups based on the Company’s industry dynamics, business model, and their influence and impact on our operations.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Stakeholder	Identified as	Channels of Communication	Channels of Communication	Frequency of	Purpose and scope of	Purpose and scope of
Group	Vulnerable or			engagement	engagement including key
	Marginalized				topics and concerns raised
	Group (Yes/No)				during each engagement
Employees	No	•	Employee Townhall	Periodically/	•	Business and
		•	Senior leadership	Quarterly/		performance updates.
			engagements	Annually	•	Pfizer’s purpose and
		•	Wellness sessions			strategy.
		•	Training programs &		•	Physical & mental
			onboarding sessions			wellbeing sessions.
		•	Internal communication		•	Code of conduct, Ethics
		•	Yammer			and compliance, Cyber
		•	Intranet portal			security.
		•	Annual Employee Pulse		•	Diversity, equity, and
			Survey			inclusion.
					•	New skills, learning &
						development.

Stakeholder	Identified as	Channels of Communication	Channels of Communication	Frequency of	Purpose and scope of	Purpose and scope of
Group	Vulnerable or			engagement	engagement including key
	Marginalized				topics and concerns raised
	Group (Yes/No)				during each engagement
Shareholders	No	•	Quarterly financial	Quarterly/	•	Financial performance
& Investors		•	statements disseminated on Stock exchanges, website of the Company and Newspaper publication. Annual Report disseminated on Stock Exchanges, website	Annually/ Need basis	• • •	Operational performance Business strategy & performance CSR programs
			of the Company.		•	Corporate governance
		•	Shareholder interaction at		•	Material changes/
			the Annual General Meeting,			disclosures/ updates.
			dissemination of the proceedings and outcome		•	Resolution of queries
			of the general meetings on
			Stock Exchanges, website of
			the Company.
		•	Press Releases.
		•	Announcement through
			Stock Exchanges, Company
			website.
		•	Dedicated email ID for
			investors.
Value Chain	No	•	In Market Visits	Event Based/	•	To enhance access to
Partners		•	Meetings	Periodically		medicines in various
						geographies.
					•	To develop a strong
						partnership for
						uninterrupted supply
						of vital medicines.
					•	To achieve higher
						market share through
						better coverage and
						penetration.
					•	To create awareness
						about portfolio and
						initiatives.
					•	Partner for credit
						worthiness and fair
						business practices.
					•	To address any query/
						feedback by value chain
						partners.
					•	To enhance awareness
						on environmental
						and sustainability
						initiatives.

Stakeholder	Identified as	Channels of Communication	Channels of Communication	Frequency of	Purpose and scope of	Purpose and scope of
Group	Vulnerable or			engagement	engagement including key
	Marginalized				topics and concerns raised
	Group (Yes/No)				during each engagement
Suppliers	No	•	Visits	Quarterly/	•	To help ensure
		•	Audits	Annually/		business continuity.
		•	Grievance Mechanism	Event Based	•	To identify and close
		•	Engagement Programs			gaps, if any, at supplier facilities related
						to Current Good
						Manufacturing Practice
						(“CGMP”).
					•	To seek their
						confirmation on
						compliance with
						Pfizer’s Suppliers Code
						of Conduct.
					•	Create awareness on
						ESG parameters.
					•	To address any
						feedback/ queries
						related to the Product.
Government	No	•	Meetings	Periodically/	Discussions of policy
		•	Communication	Regulatory/	matters such as access
		•	Public Consultation through	Reporting/	and	affordability, pricing,
			industry associations	Quarterly/	availability of new therapies
				Annually	in Government programs,
					regulatory processes etc.

Leadership Indicators

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.

Pfizer firmly believes in the importance of stakeholder engagement for cultivating lasting relationships and identifying potential risks and opportunities. We have established various channels to engage with stakeholders on responsible business growth topics. Consultation on these matters is delegated to relevant departments, to foster continuous engagement. Our risk management approach allows us to periodically share feedback on significant risks and opportunities with the Board. Our engagement with stakeholders aids us in identifying our priorities, guiding our strategy.

2. Whether stakeholder consultation is used to support the identification and management of environmental, and social topic? (Yes/No)

If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

At Pfizer, we recognize the importance of stakeholder consultation in navigating the complexities of our ever-evolving world. We engage with a variety of stakeholders to inform our decision-making processes and provide us with insights as we work to advance our business responsibly.

3. Provide detail of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

At Pfizer Limited, we constantly strive to positively impact the health of people across the country. The Company, through its Corporate Social Responsibility (“CSR”) Policy, encourages stronger commitment from the organization and employees towards the society to address the healthcare challenges of the country. Our focal CSR initiatives include fostering young Indian minds and their cutting-edge innovations in healthcare; curbing Anti-Microbial Resistance (“AMR”) in time, registering the resistance together; unburdening cancer patients through cancer care initiatives; and working towards hygiene and sanitation in rural and semi-urban areas; creating social impact through volunteering; and transforming lives, one village at a time.

Principle 5: Businesses should respect and promote human rights.

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

==> picture [454 x 37] intentionally omitted <==

		E	mployees
Permanent	1,563	1,563	100%	1,685 1,685 100%
Other thanpermanent	170	170	100%	210 210 100%
Total Employees	1,733	1,733	100%	1,895 1,895 100%
			Workers
Permanent	35	35	100%	36 36 100%
Other thanpermanent	–	–	–	– – –
Total Workers	35	35	100%	36 36 100%

Note: Training concerning Human Rights components is integrated into Pfizer’s Blue Book, a mandatory module for all permanent and non-permanent employees and permanent workers within the Company. To facilitate this, the Company has implemented an e-module based on the Blue Book for employee training. Furthermore, all employees and permanent workers engaged in procurement-related roles supporting manufacturing and supply operations undergo training on Pfizer’s global labour and human rights standards.

In FY 2023-24 certain colleagues have been re-grouped.

2. Details of minimum wages paid to employees and workers, in the following format:

Category		Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24	Current Financial Year 2024-25 Previous Financial Year 2023-24
	Total (A)	Equal to Minimum Wage More than Minimum Wage Total (D) Number (B) % (B/A) Number (C) % (C/A)					Equal to Minimum Wage More than Minimum Wage
							Number (E) % (E/D) Number (F) % (F/D)
Employees
Permanent	1,563	–	–	1,563	100%	1,685	– – 1,685 100%
- Male	1,316	–	–	1,316	100%	1,382	– – 1,382 100%
- Female	247	–	–	247	100%	303	– – 303 100%
Other than Permanent	170	–	–	170	100%	210	– – 210 100%
- Male	80	–	–	80	100%	110	– – 110 100%
- Female	90	–	–	90	100%	100	– – 100 100%
Workers
Permanent	35	–	–	35	100%	36	– – 36 100%
- Male	35	–	–	35	100%	36	– – 36 100%
- Female	0	–	–	0	–	0	– – 0 –
Other than Permanent	–	–	–	–	–	–	– – – –
- Male	–	–	–	–	–	–	– – – –
- Female	–	–	–	–	–	–	– – – –

3. Details of remuneration/ salary/ wages, in the following format for FY 2024-25:

a. Median remuneration/ wages:

Median remuneration/ wages:
	Male Female
	Number Median salary/ wage of respective category Number Median salary/ wage of respective category
Board of Directors (BoD)	4 86,29,605 3 23,90,000
Key Managerial Personnel (KMP)	3^ 1,47,99,210 1^ 9,48,34,802
Employees other than BoD and KMP	1,315 11,47,509 248 14,82,533
Workers	35 7,04,504 0 –

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

Gross wages paid to females as % of total wages paid by the entity, in the following format:	Gross wages paid to females as % of total wages paid by the entity, in the following format:	Gross wages paid to females as % of total wages paid by the entity, in the following format:
Current Financial Year 2024-25 Previous Financial Year 2023-24*
Gross wages paid to females as % of total wages	28.99%	25.26%

*: The data for FY 24-25 includes the gross wages for total employees i.e., permanent employees and other than permanent employees.

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes, the Company has an Employee Relations Investigations Group for addressing matters and issues related to human rights. The Company has further formulated Internal Complaints Committee which addresses sexual harassment related grievances as per POSH Policy. The Company is also aligned with Pfizer Inc.’s human rights diligence program. Pfizer maintains a focused human rights diligence program, which outlines our management approach in our supply chain and our operations.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

The Company is committed to conducting business in an ethical and responsible manner. This includes respecting human rights throughout its operations. The Company has a whistleblower mechanism and open-door policy wherein any employee irrespective of hierarchy has access to the Employee Relations Investigations Group, and in appropriate cases, to the Corporate Compliance Group. For all grievances that are routed to the Employee Relations Investigations Group and in certain cases to the Corporate Compliance Group, necessary action is taken in line with the underlying internal polices and regulations applicable to the workplace. The Company also has the Internal Complaints Committee (ICC) which addresses sexual harassment related grievances. Any case that is raised is thoroughly and confidentially investigated. If found guilty, appropriate action is taken against the accused. In appropriate and exceptional cases, concerns may be raised directly to the Chairman of the Audit Committee of the Company. The Company has a zero-retaliation policy in place designed to ensure no adverse actions against the complainant.

Many channels exist for raising questions and reporting concerns, including the Compliance Helpline (thirdparty public hotline available by phone or web, with anonymous reporting were allowed under local law), the Compliance Division (through email, phone, fax, mail and directly to colleagues), management, and other channels supported by our Open Door Policy (which includes our whistleblower policy). This policy encourages colleagues to present ideas, ask questions, and raise concerns. Retaliation against anyone who seeks advice, raises a concern, reports misconduct, or provides information in an investigation is strictly prohibited by our policy that protects whistleblowers. In addition, our Ombuds Office is an available resource to support colleagues with information and guidance to help them address work-related issues.

6. Number of complaints on the following made by employees and workers:

==> picture [456 x 46] intentionally omitted <==

----- Start of picture text -----

Current Financial Year 2024-25 Previous Financial Year 2023-24
Pending Pending
Filed during resolution at Remark Filed during resolution at Remark
the year end of year the year end of year
----- End of picture text -----


Sexual Harassment	1	–	–	1 – –
Discrimination at workplace	–	–	–	– – –
Child Labour	–	–	–	– – –
Forced Labour/ Involuntary Labour	–	–	–	– – –
Wages	–	–	–	– – –
Other human rights related issues	–	–	–	– – –

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 in the following format:

Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 in the following format:	Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 in the following format:	Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 in the following format:
Current Financial Year 2024-25 Previous Financial Year 2023-24
Total complaints reported under Sexual Harassment on Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH)	1	1
Complaints on POSH as a % of female employees/ workers	0.3%	0.3%
Complaints on POSH upheld	–	–

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

At Pfizer, our senior leaders and management set the tone for a strong culture of integrity and encourage colleagues and partners to raise concerns without fear of retaliation. Retaliation against anyone who seeks advice, raises a concern, reports misconduct, or provides information in an investigation is strictly prohibited by our anti-retaliation policy that protects whistleblowers. The Company has adopted a policy in accordance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 whereby an aggrieved woman can submit a complaint which must be investigated by the Internal Complaints Committee with absolute confidentiality.

The Company has in place a whistle-blower / vigil mechanism through which its directors, employees and stakeholders can report their genuine concerns about illegal or unethical behaviour, actual or suspected fraud or violation of the Company’s code of conduct or ethics policy. The mechanism provides for safeguards against victimization of persons who use such mechanism. If any individual, regardless of his or her role in the Company, retaliates against an employee who has truthfully and in good faith reported a potential violation, the Company will take appropriate action—even if it later turns out that the employee was mistaken in reporting the matter originally. The Company also conducts training and awareness programs for all its employees on periodic basis to embed a Speak Up Culture.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Yes, Pfizer is committed to conducting business in an ethical and responsible manner. The Company is committed to conducting business ethically and responsibly, including respecting and upholding human rights principles throughout its operations and business relations.

The contracts which the Company executes with its suppliers contain obligations on the suppliers to comply with all applicable laws. Further, after suppliers are selected and onboarded, they are expected to comply with the Company’s Responsible Sourcing Guidelines and Supplier Conduct Principles which are aligned to the Pharmaceutical Supply Chain Initiative.

10. Assessment for the FY 2024-25:

Assessment for the FY 2024-25:
	% of plants and offices that were assessed
	(by entity or statutory authorities or thirdparties)
Child Labour	100%
Forced/ Involuntary Labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%

11. Provide details of any corrective actions taken or underway to address significant risks/ concerns arising from the assessments at Qs. 9, above.

No significant risk or concern was identified during the reporting period.

Leadership Indicators

1. Details of a business process being modified/ introduced as a result of addressing human rights grievances/ complaints.

Not Applicable.

2. Details of the scope and coverage of any Human Rights due diligence conducted.

The Company relies on its parent company Pfizer Inc.’s. global human rights diligence program. Pfizer’s established risk-based evaluations for suppliers, including contract manufacturers and other suppliers deemed to be high-risk, assess environment, health, safety (EHS), and sustainability performance, including labour and human rights reviews. When assessing whether a supplier is high-risk, we consider the supplier’s geography, industry, and other proprietary and public domain information. The risk-based assessment process results in a supplier risk score. Suppliers that are determined to have an elevated risk, e.g., EHS and labour and human rights risks, are subject to a governance process which may result in the supplier being required by Pfizer to develop corrective actions to improve their operations and procedures and/or mitigate identified risks. If the supplier does not comply with the agreed corrective actions, Pfizer may seek an alternative supplier. Additionally, Pfizer Limited has strong internal processes and checks to help ensure compliance on human rights and related topics.

3. Is the premise/ office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes. Following arrangements are provided at the Company’s premises: dedicated parking, security support, disabled-friendly washrooms, adequate space for wheelchair movement, visual and audio alarms, emergency evacuation chair, ramps in the basement at entry points, etc. The Company continues to work towards identifying the needs of employees with disabilities and proactively supporting them in diligently carrying out their dayto-day duties without any challenge(s). At Company’s Goa premises, infrastructure study for accessibility is undertaken and the Company has identified infra-improvement areas which the Company continues to work towards to ensure a safe, health, equitable, and inclusive work environment for all its employees, including those with disabilities.

4. Details on assessment of Value Chain Partners:

	% of value chain partners (by value of business done with
	suchpartners) that were assessed:
Child Labour	100%
Forced/ Involuntary Labour	100%
Sexual harassment	100%
Discrimination at workplace	100%
Wages	100%

Note: As part of your Company’s onboarding process all risks associated with labour rights and health and safety conditions are assessed for all value chain partners. Regular audits are also conducted to track and monitor compliance with the above.

5. Provide details of any corrective actions taken or underway to address significant risks/ concerns arising from the assessment at Qs. 4 above.

The Company has not received any complaints on Child Labour, Forced/ Involuntary Labour/ Sexual Harassment/ Discrimination at workplace/ Wages from the Value Chain Partners through any of the existing public and internal grievances channels described above.

Principle 6: Businesses should respect and make efforts to protect and restore the environment. Essential Indicators

1. Details of total energy consumption and energy intensity, in the following format:

Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24
From ‘Renewable Sources’
TotalElectricityConsumption (A) – Solar & Wind	10,947	9,024
TotalFuelConsumption (B)	–	–
Energyconsumption through Other Sources (C)	–	–
Total Energy Consumption from renewable sources (A+B+C)	10,947	9,024
From ‘Non-Renewable Sources’
TotalElectricityConsumption (D)	8,018	12,444
TotalFuelConsumption (E)	803	760,687
Energyconsumption through Other Sources (F)	–	–
Total Energy Consumption from non-renewable sources (A+B+C)	8,821	773,131
Total Energy Consumption (RE + Non-RE)	19,768	782,155
Energy intensity per rupee of turnover (Total energyconsumption/turnover in rupees)	0.00000087	0.000036
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity*(Total energy consumed/ Revenue from operations adjusted for PPP)	0.0000179	0.000816
Energy intensity in terms of physical output(Based on number of strips)	0.00016	0.00430

*: As per IMF Database, purchasing power parity (PPP) for India is 20.66 (INR.) per international dollar (USD) as March 2025, https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC.

2. Does the entity have any sites/ facilities identified as designated consumers (DCs) under the Performance, Achieve, and Trade (PAT) Scheme of the Government of India? (Yes/No)

If “Yes”, disclose whether targets set under the PAT Scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.

Not Applicable, as the Company does not fall in the category of industries mandated under PAT Scheme of Government of India.

3. Provide details of the following disclosures related to water, in the following format:

Provide details of the following disclosures related to water, in the following format:	Provide details of the following disclosures related to water, in the following format:	Provide details of the following disclosures related to water, in the following format:
Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24
Water withdrawal by source (in kilolitres- Kl)
(i) Surface Water	–	–
(ii) Groundwater	17,553	20,585
(iii) Third PartyWater	7,751	17,637
(iv) Seawater/ Desalinated water	–	–
(v) Others: Tankers	9,951	–
Total Volume of water withdrawal (in KL)(i + ii + iii + iv + v)	35,255	38,222
Total volume of water consumption (in KL)	35,255	38,222
Water intensity per rupee of turnover(water consumed/ turnover)	0.0000015	0.0000017
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)*(Total water consumption/ Revenue from operations adjusted for PPP)	0.0000319	0.0000399
Water intensity in terms of physical output(Based on number of strips)	0.00028	0.00021

*: As per IMF Database, purchasing power parity (PPP) for India is 20.66 (INR.) per international dollar (USD) as March 2025, https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC.

4. Provide the following details related to water discharge:

Provide the following details related to water discharge:	Provide the following details related to water discharge:	Provide the following details related to water discharge:
Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24
Water discharge by destination and level of treatment (in kiloliters)
(i). To Surface Water	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(ii). To Ground Water	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(iii). To Seawater	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(iv). Sent to Third Parties	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(v). Others	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
Total water discharged(in kilo-litres)	–	–

Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Yes/No). If “Yes”, name the external agency.

5. Has the entity implemented a mechanism for Zero Liquid Discharge (ZLD)? If “Yes”, provide details of its coverage and implementation.

Pfizer Limited’s Goa manufacturing plant has an onsite wastewater treatment facility which treats the wastewater at three levels i.e., Primary, Secondary and Tertiary treatment in line with the current site Consent as per the local government norms.

6. Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:

Parameter Please specify unit*	Current Financial Year 2024-25	Previous Financial Year 2023-24
NOx ppmv	700.2	635.3
SOx Kg/hr	0.007	6.16
Particulate Matter (PM) mg/Nm3	10.1	15.6
Persistent organicpollutant (POP) Volatile organic compounds (VOC) Hazardous airpollutant (HAP)	Not applicable

*: NOx, SOx and PM are as per the source emission monitoring report for Diesel Generators at Goa Plant. Further the Company does not measure POP, VOC, and HAP as per Consent conditions.

7. Please provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) and its intensity, in the following format:

Parameter Please specify unit Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Please specify unit Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Please specify unit Current Financial Year 2024-25 Previous Financial Year 2023-24
Total Scope 1 Emissions(Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) Metric tonnes of CO2 equivalent	56	57
Total Scope 2 Emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available) Metric tonnes of CO2 equivalent	1,619	2,475
Total Scope 1 and Scope 2 emissions per rupee of turnover Metric tonnes of CO2 equivalent/ INR	0.000000073	0.00000012
Total Scope 1 and Scope 2 emissions per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 & 2 emissions/ Revenue from operations adjusted for PPP) Metric tonnes of CO2 equivalent/ PPP	0.00000152	0.00000264
Total Scope 1 and Scope 2 emission intensity in terms of physical output(Based on number of strips) Metric tonnes of CO2 equivalent/ No. of strips	0.000014	0.000014

*: As per IMF Database, purchasing power parity (PPP) for India is 20.66 (INR.) per international dollar (USD) as March 2025, https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC.

8. Does the entity have any project related to reducing Greenhouse gas emissions? If “Yes”, then provide details.

Yes, the Company follows stringent environmental and health standards and has created a model for environmental sustainability with focus on conservation of resources, renewable energy, and waste minimization. The Company’s Head Office has opted for Green Power tariff under ‘Switch to Green initiative’ from February 1, 2023, and accordingly the power requirement at the Head Office is sourced through renewable sources of energy. The Company is working towards Pfizer enterprise level goal of achieving the voluntary Net-Zero Standard by 2040.

The Company has installed 1,500 KWP of solar panels at the Goa manufacturing plant as a part of the Company’s continued journey toward renewable energy and this solar project provides 53% of the Goa plant’s total energy needs during FY 2024-25.

9. Provide details related to waste management by the entity, in the following format:

Provide details related to waste management by the entity, in the following format:	Provide details related to waste management by the entity, in the following format:	Provide details related to waste management by the entity, in the following format:
Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24
Total Waste Generated(in metric Tonnes)
Plastic Waste(A)	45.86	48.91
E-Waste(B)	1.19	1.04
Bio-medical Waste(C)	0.28	0.29
Construction and Demolition Waste(C&D) (D)	–	–
BatteryWaste(E)	2.46	–
Radioactive Waste(F)	–	–
Other Hazardous Waste generated (G) (Please specify,if any)	33.32	30.34
Other Non-Hazardous Waste generated (H) (Please specify,if any)	60.09	69.85
Total Waste Generated(A+B+C+D+E+F+G+H)	143.21	150.43
Waste intensity per rupee of turnover (Total wastegenerated/ Revenue from operations)	0.000000006	0.00000001
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)*(Total waste generated/ Revenue from operations adjusted for PPP)	0.00000013	0.00000016
Waste intensity in terms of physical output(Based on number of strips)	0.0000012	0.0000008
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)
Category Waste
(i) Recycled	100.86	111.95
(ii)Re-used	–	–
(iii)Other recoveryoperations	1.19	5.72
Total	102.05	117.67
For each category of waste generated, total waste disposed by nature of disposal method(in metric tonnes)
Category Waste
(i) Incineration	32.42	32.76
(ii)Landfilling	–	–
(iii)Other disposal operations	8.74	–
Total	41.16	32.76

*: As per IMF Database, purchasing power parity (PPP) for India is 20.66 (INR.) per international dollar (USD) as March 2025, https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Pfizer has a long history of using the concepts of green chemistry and promoting them across the industry. Through scientific innovation Pfizer strives to design more efficient processes that can reduce the environmental impact of our medicines throughout the product life cycle. Central to Pfizer’s sustainable medicines program is the minimization of waste across all sites globally. We recognize that climate change poses significant risks to global health as well as to our business operations and our sites consistently seek opportunities to reduce, reuse, repurpose, and recycle materials such as packaging and plastics. The Company has adopted waste management systems in compliance with regulatory requirements, Pfizer’s Global EHS policy, and the Company’s internal EHS policy. Plastic waste generated from the Company’s operations at its manufacturing site in Goa is disposed of in accordance with the Plastic Waste Management Rules, 2016. The Goa Plant has undertaken continuous improvement projects (example: yield improvement, reduction in paper consumption etc.) in line with Pfizer internal enterprise environmental sustainability goals.

11. If the entity has operations/ offices in & around ecologically sensitive areas where environmental approvals/ clearances are required, please specify details in the following format:

Location of operations/	Type of operations	Whether the conditions of
offices		environmental approval/ clearance are
		being complied with? (Yes/No)
		If “No”, the reasons thereof and
		corrective action taken, if any.
	Not applicable.

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year 2024-25:

Name and brief of	EIA	Whether conducted	Results	Relevant
the project	Notification	by independent	communicated in	Web-link
	No.	agency (Yes/No)	public domain (Yes/
			No)

As per the notification issued by the Ministry of Environment, Forests and Climate Change (‘MoEFCC’) in India, an Environmental Impact Assessment (EIA) is supposed to be carried out for industries which have an adverse impact on the environment. The pharmaceutical sector was not identified as an industry which requires an EIA preclearance by the MoEFCC.

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment Protection Act and Rules thereunder (Yes/ No).

If “Not”, provide details of all such non-compliances, in the following format:

Specify the law/	Provide details of the	Any fines/ penalties/	Corrective action
regulation/ guidelines	non-compliance	action taken by regulatory	taken, if any
which is not compliant		agencies such as pollution
		control board or by courts

Yes, the Company has complied with all the environment related applicable legislations during the financial year ended March 31, 2025.

Leadership Indicators

1. Water withdrawal, consumption, and discharge in areas of ‘Water Stress’ (in kilo litres):

For each facility/ plant located in areas of water stress, provide the following information:
i. Name of area
ii. Nature of operations
iii. Water withdrawal, consumption, and discharge in the following format:

Parameter	Current Financial Year 2024-25	Previous Financial Year 2023-24
Water withdrawal by source (in kilo litres)
(i) Surface Water	–	–
(ii) Ground Water	–	–
(iii) Third PartyWater	–	–
(iv) Seawater/ Desalinated Water	–	–
(v) Others	–	–
Total volume of water withdrawal (in KL)	–	–
Total volume of water consumption (in KL)	–	–

Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24	Parameter Current Financial Year 2024-25 Previous Financial Year 2023-24
Water intensity per rupee of turnover (Water consumed/ Turnover)	–	–
Water intensity(optional)- the relevant metric may be selected bythe entity	–	–
Water discharge by destination and level of treatment (in Kilo litres)
(i) To Surface Water	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(ii) To Ground Water	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(iii) Sent to Third Party Water	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(iv) Into Seawater	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
(v) Others	–	–
- No treatment	–	–
- With treatment-please specifylevel of treatment	–	–
Total water discharged. (in kilo-litres- Kl)	–	–

Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Yes/No). If “Yes”, name the external agency.

2. Please provide details of total Scope 3 emissions and its intensity, in the following format:

Parameter	Please specify unit	Current Financial	Previous Financial
		Year 2024-25	Year 2023-24
Total Scope 3 Emissions(Break-up of the GHG	Metric tonnes of
into CO2, CH4, N2O, HFCs, PFCs, SF6, NF3, if	CO2 equivalent
available)
Total Scope 3 emissions per rupee of turnover	–	Not applicable
Total Scope 3 emission intensity(optional)-	–
the relevant metric may be selected by the
entity

3. With respect to the ecologically sensitive areas reported in Qs. 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along with prevention and remediation activities.

Not applicable.

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions/ effluent discharge/ waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

S.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided	Outcome of the Initiative	Outcome of the Initiative	Outcome of the Initiative
No.		along with summary)
1.	Shift to Renewable	The Goa manufacturing site has initiated full utilization	53% reduction		in
	Energy	of its installed solar power project i.e., 1,500 Kwp.	convention	power
		This move has significantly reduced Goa Plant’s	consumption in FY 2025
		dependency on non-renewable source of energy,	over the previous	year.
		leadingto reduction in emissions.
2.	Wastewater	The Company has in-house full-fledged Wastewater	The treated water		is
	Management	Treatment Plant (WTP) with primary, secondary, and	used for gardening and
		tertiary treatment facility to treat wastewater, recycle	utility purposes	within
		it, and reuse it forgardeningand other utility purposes.	the facility.
3.	Water Recycling	The Company has Condensate Recovery system for Air	1,620 kL of	water
		Handling Units to recycle and reuse water to minimize	recycled and	reused
		dependencyon freshwater and optimize water usage.	since June 2024.
4.	Waste Management	Effluent Treatment Plant (ETP) sludge de-watering	Sludge management
	Initiatives	system. Previously sludge was de-watered over four
		big Sand Bed and dried over natural ventilation.
		Annually, all the sand beds are replaced and disposed
		as hazardous waste. The Sludge Dewatering system
		separates the sludge using SQUIZING technology in a
		semisolid state without use of anySand Dryingbed.
5.	Zero Waste to Land	Recycling of waste through government approved	22.28 Metric Tonnes		of
	fill	Vendors i.e., plastic waste, e-waste, battery waste, and	waste is recycled.
		other non-hazardous waste (composting of food waste
		generated, sanitary bin waste, general waste, paper,
		metal).

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web-link.

At Pfizer, Business Continuity Management (BCM) is proactively integrated into strategic and operational plans to enable the continuity of key business activities by establishing a strong program that identifies, evaluates, and mitigates potential threats / vulnerabilities to business activities. The program also ensures that the Company has response capability to safeguard the interests of key stakeholders, and the reputation of Pfizer and our brands in the event of a threat being realized. This applies to all Pfizer business operations and promotes a culture based on minimizing loss, mitigating disruption, and recovery of critical activities.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.

There were no events arising from the Value Chain Partners of Company, having any significant adverse impact to the environment. In addition, the Company continues to prioritize emission reduction by deploying highefficient production machinery and utility systems, focusing on energy conservation. As a result of this, the Company’s Goa plant has successfully achieved a 31.6% reduction in GHG emissions.

Further, the Company has significantly enhanced its air-to-ocean supplies from global sites, contributing to a reduction in carbon emissions and ranking among the top three markets in this initiative globally.

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

Nil.

8. How many “Green Credits” have been generated or procured:

a. By the listed entity.
b. By the top ten (in terms of the value of purchases and sales, respectively) value chain partners.
- Nil.

Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent.

Essential Indicators

1. (a) Number of affiliations with trade and industry chambers/ associations.

  - The Company is affiliated with 5 (five) trade and industry chambers / associations.

(b) List the top 10 trade and industry chambers/ associations (determined based on the total numbers of such body) the entity is member of/ affiliated to.

body)	the entity is member of/ affiliated to.
S.	Name the trade and industry chambers/ associations	Reach of trade and industry chambers/
No.		associations (State/ National)
1.	Organization of Pharmaceutical Producers of India (OPPI)	National
2.	Federation of Indian Chambers of Commerce and Industry	National
	(FICCI)
3.	US India Strategic Partnership Forum (USISPF)	National
4.	US India Business Council (USIBC)	National
5.	The Bombay Chamber of Commerce and Industry	State

2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.

Name of authority Brief of the Case Corrective action taken

The Company has not received any order from regulatory authorities on anti-competitive conduct during the financial year 2024-25.

Leadership Indicators

1. Details of public policy positions advocated by the entity:

S.	Public policy	Method resorted	Whether information	Frequency of	Web Link, if
No.	advocated	for such advocacy	available in public	Review by Board	available
			domain (Yes/No)

Pfizer through various Industry associations and chambers has been advocating its opinion, voice, and thoughts on policies and requirements in the pharmaceutical sector, that will aid pharma companies on a steady path to responsible and sustained growth trajectory and help serve the patients.

Principle 8: Businesses should promote inclusive growth and equitable development. Essential Indicators

1. Details of Social Impact Assessments (SIA) projects undertaken by the entity based on applicable laws, in the current financial year 2024-25:

Name and brief	SIA	Date of	Whether conducted by	Results	Relevant
detail of project	Notification	notification	independent external	communicated	web-link
	No.		agency (Yes/ No)	in public domain
				(Yes/No)
		Not	applicable.

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:

S.	Name of the project	No. of project affected	%of PAFs	Amounts paid to PAFs
No.	for which R&R is	families (PAFs)	covered by R&R	in the FY (in INR.)
	ongoing
		Not applicable.

3. Describe the mechanisms to receive and redress grievances of the community.

The Company has established a whistleblower / vigilance mechanism that enables its directors, employees, and stakeholders to report any concerns regarding illegal or unethical behavior, suspected fraud, or violations of the Company’s code of conduct or ethics policy. This mechanism includes robust safeguards to protect individuals from any form of retaliation for using it. Many channels exist for raising questions and reporting concerns, including the Compliance Helpline (third-party public hotline available by phone or web, with anonymous reporting were allowed under local law) .

4. Percentage of input material (input to total inputs by value) sourced from suppliers:

Percentage of input material (input to total inputs by value) sourced from suppliers:	Percentage of input material (input to total inputs by value) sourced from suppliers:	Percentage of input material (input to total inputs by value) sourced from suppliers:
Current Financial Year 2024-25 Previous Financial Year 2023-24
Directly sourced from MSMEs/ Smallproducers	11%	14%
Directly from within India	59%	58%

5. Job creation in smaller towns: Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/ on contract basis) in the following locations, as % of the total wage cost:

Job creation in smaller towns: Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/ on contract basis) in the following locations, as % of the total wage cost:	Job creation in smaller towns: Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/ on contract basis) in the following locations, as % of the total wage cost:	Job creation in smaller towns: Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/ on contract basis) in the following locations, as % of the total wage cost:
Location Current Financial Year 2024-25 Previous Financial Year 2023-24
Rural	0.17%	0.14%
Semi-Urban	1.31%	1.08%
Urban	9.38%	8.05%
Metropolitan	89.15%	90.73%

Note: Place to be categorized as per RBI Classification System- rural/ semi-urban/ urban/ metropolitan

Leadership Indicators

1. Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments

Assessments
Details of negative social impact identified		Corrective action taken
	Not applicable

2. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:

as identified by government	bodies:
S. No.	State	Aspirational District	Amount Spent (in INR.)
None of the CSR projects	undertaken by	the Company fall under aspirational	districts as identified by
Government bodies.

3. (a) Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized/ vulnerable groups? (Yes/No) No

(b) From which marginalized/ vulnerable groups do you procure? Not applicable.
(c) What percentage of total procurement (by value) does it constitute? Not applicable.

	(c) What percentage of total procurement (by value) does it constitute? Not applicable.
4.	Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year 2024-25), based on traditional knowledge:
	S. No. Intellectual Property based on traditional knowledge Owned/ Acquired (Yes/No) Benefit Shared (Yes/ No) Basis of calculating benefit share
	Not applicable.

5. Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.

5.	Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.
6.	Name of authority Brief of Case Corrective action taken
	Not applicable.
	Details of beneficiaries of CSR Projects:
	S. No. CSR Project No. of persons benefited from CSR Projects % Beneficiaries from vulnerable & marginalized groups
	1. Pfizer-cancer care physical helpdesk– Project Aashta- Cancer Helpdesks through ‘Doctors for You’, is a program that works to provide aid to cancer patients during their diagnosis, treatment, and rehabilitation phase. The Project is aimed at establishing a support system that facilitates the best available care to oncology patients. Project Aastha has a functioning helpline number, ensuring rapid and effective response to the patients. The Cancer Helpdesk is a step towards the betterment of the community, and the Company aims to serve the patients with care and support as well as emotional counselling to patients and caregivers in need. 6,75,633 100%
	2. Goa Community Development The project aims strengthening of health and education facilities at Borim (SHEF) including upgradation of government primary schools in terms of construction classrooms/ computer labs equipment. Anganwadis to be renovated along with the kitchen and WASH facility, also health education in schools to bring about positive behavioural change to improve overall health of school children. As part of this activity, the program reached out to 3 schools and 4 Anganwadis. 509 students 100%
	3. Project Parivartan and Online Learning Platform: Americares India Foundation with the support of Pfizer, has been actively working with 11 hospitals across 8 states to seamlessly integrate IPC and AMS in the system by equipping medical professionals with required knowledge and techniques. ates of Ventilator associated pneumonia (VAP), Central line associated blood stream infections (CLABSI) and Catheter associated urinary tract infections (CAUTI) have been sustained as per the standard benchmark in all partner hospitals. Appx. 1.15 lakhs –

S.	CSR Project	No. of persons	% Beneficiaries
No.		benefited from	from vulnerable &
		CSR Projects	marginalized groups
4.	Pfizer – Tata Trusts	277,318	68%
	Cancer Care Project, aims to reduce cancer-related morbidity and
	mortality in the target community by increasing awareness, promoting
	early detection through accessible screening services, and strengthening
	local capacity to support prevention, diagnosis, and care. Tata Cancer
	Care Foundation set-up by Tata Trusts to implement the cancer care
	programme, is based on the four pillars of access, affordability, quality,
	and awareness. TCCF is committed to downstaging the impact of the
	disease by facilitating early detection by building awareness, screening,
	and improving the quality of life of cancer patients and their families.
5.	Tata Mumbai Marathon 2025 - A Home away from Home,St Jude provides	489	100%
	hygienic accommodation, and nutritious food to children undergoing
	cancer treatment. The funding is for supporting maintenance, ration, and
	transport costs for a center for family units, to improve the quality of life
	for children and families supported from different parts of the country.
6.	Pfizer INDovation NIPER-A:Pfizer INDovation NIPER-A Edition program	Not	applicable
	supports six early-stage screening and diagnostic product start-ups
	with INR 25 lakh grant each and expert mentorship to complete product
	development, preclinical trials, and customer discovery surveys. Anchored
	by NIPER Ahmedabad, Pfizer, and Social Alpha, and supported by the
	Department of Pharmaceuticals and NITI Aayog, the one-year program
	accelerator will run from September 2024 to September 2025.
7.	Pfizer INDovation 2025 Program:The program will support start-ups	Not	applicable
	with innovative solutions in the healthcare ecosystem to aid healthcare
	system professionals and front-line workers in providing quality care at
	affordable costs. The theme is Primary Health care, with specific focus
	areas of Oncology, NCDs, Maternal and Child Health, Immunisation, and
	Brain Health. The 24-month program will consist of 2 tracks: ‘Product
	Development’ to support deep-tech healthcare innovations navigate
	through clinical validation and regulatory pathways, and ‘Solution
	Deployment’ to deploy validated innovations in the primary healthcare
	system, with 7 start-ups supported in each track.

Principle 9: Business should engage with and provide value to their consumers in a responsible manner.

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

The Company treats customer complaints with utmost importance and has established a mechanism for addressing and redressal of customer complaints. The Company also has a dedicated team for receiving consumer complaints and feedback, which is thereafter shared with the respective departments. All the grievances received through various available channels are registered and tracked with a unique number through the global Complaint management system. Grievances are addressed / resolved through investigation and thereafter response is provided to customer. The Company has dedicated helpline numbers and Email ID through which patients / consumers, healthcare professionals and other stakeholders can approach the Company for reporting adverse events or product related complaints. Additionally, the Company’s field force receives product related complaints / Adverse Events which are shared with the respective departments. More details can be found on the link Pfizer India Customer Care No. | India Customer Care. The customer complaints received at Contactus. [email protected] are managed in accordance with the standard procedure. Based on its nature, the complaint is forwarded to the respective department for their further action.

Pfizer employees are also responsible for reporting safety information they may encounter even when not at work.

2. Turnover of products and/services as a percentage of turnover from all products/services that carry information about:

about:
Parameters	As percentage to total turnover
Environmental and social parameters	–
relevant to theproduct
Safe and responsible usage	100%

The product label has all required details as per labeling regulation of India. The disposal after usage by customer/ patient is not under purview of the company. The finished products stored at Pfizer sites/ warehouses are disposed / destroyed safely at government approved destruction sites.

Recycling and/or safe disposal

3. Number of consumer complaints in respect of the following:

	Current Financial Year 2024-25	Current Financial Year 2024-25	Remarks	Previous Financial Year 2023-24 Remarks Received Pending at end of year
	Received Pending at end of year
Data Privacy	–	–	–	– – –
Advertising	–	–	–	– – –
Cyber-security	–	–	–	– – –
Delivery of essential services	–	–	–	– – –
Restrictive Trade Practices	–	–	–	– – –
Customer Complaints	149*	16	Pending complaints are under investigation	208* 5 –

*: Also forms part of complaints reported under ‘Customers’ under Section A(VII)(23) of this report.

4. Details of instances of product recalls on account of safety issues:

	Number	Reasons for Recall
Voluntary Recalls	1	During the applicable reporting period (April 1, 2024, to March 31, 2025), the
		Company had initiated one Voluntary recall at wholesale level of Minesse
		Tablets manufactured and marketed by Pfizer Limited in India market. The
		recall was initiated following an out of specification results observed for Assay
		Test during routine stability sample testing. As a precautionary measure,
		the Company initiated recall at wholesale level for all batches of these SKUs
		manufactured and marketed within shelf life from the respective distributors.
Forced Recalls	–	–

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No).

If available, provide a web-link of the policy.

Yes, The Company has implemented a Cybersecurity Policy to address data privacy risks comprehensively. Recognizing the criticality of safeguarding Sensitive Information, we have devised a framework aimed at preventing unauthorized access and piracy of data.

Our Privacy Policy, accessible on the Company’s website at https://www.pfizerltd.co.in/privacy, outlines our commitment to protecting data privacy and serves as a guide for stakeholders on how we handle and secure their information.

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services, cyber security, and data privacy of customers; re-occurrence of instances of product recalls, penalty/ action taken by regulatory authorities on safety of products/ services.

Not applicable.

7. Provide the following information relating to data breaches during FY 2024-25:

(a) Number of instances of data breaches:

Nil

(b) Percentage of data breaches involving personally identifiable information of customers. Nil
(c) Impact, if any, of the data breaches.
Nil

Leadership Indicators

1. Channels/ platforms where information on products and services of the entity can be accessed

https://www.pfizerltd.co.in/

2. Steps taken to inform and educate consumers about safe and responsible usage of products and/ or services.

Pfizer Medical Information team responds to unsolicited inquiries coming from consumers. We would provide relevant information from an approved patient information leaflet as available and direct the consumer to their treating physician for further information.

3. Mechanism in place to inform consumers of any risk of disruption/ discontinuation of essential services.

The Company has put in place a mechanism to notify the regulatory authorities of any instance of product shortage/ disruption or product availability, etc.

4. (a) Does the entity display product information on the product over and above what is mandated as per the local laws? (Yes/ No/ Not Applicable). If “Yes”, provide details in brief.

The Company does not display additional information other than the information mandated as per the local laws. However, all relevant information like storage conditions, product safety, usage, contact information, wherever applicable is displayed on the product label for consumer information and dissemination as per statutory and regulatory norms.

(b) Did your entity carry out any survey about customer satisfaction relating to the major products/ services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/ No).
The Company conducted customer relationship survey through the Qualtrix platform for its first paying customers to gauge the satisfaction level and experience measure trends of the customers about Pfizer Limited. The key attributes covered as part of the survey included parameters related to effectiveness of meeting needs, ease of doing business, experience as a customer, and performance trend over time.

For and on behalf of Board of Directors

Meenakshi Nevatia	Pradip Shah
Managing Director	Chairman
DIN:08235844	DIN:00066242

AI assistant

Pfizer Ltd. — Environmental & Social Information 2025

60507_rns_2025-06-29_33ed99bc-f536-4d03-b5c8-9c9547f2622b.pdf

Pfizer Limited

June 29, 2025

Dear Sirs,

Sub: Business Responsibility & Sustainability Report for the Financial Year 2024 – 25.

Prajeet Nair

Director – Corporate Services & Company Secretary

Annexure – G BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT (“BRSR”)

Section A: General Disclosures

I. Details of the listed entity:

II. Products/ Services:

16. Details of business activities (accounting for 90% of the turnover):

17. Product/ Services sold by the entity (accounting for 90% of the entity’s turnover):

III. Operations:

18. Number of locations where plants and/or operations/ offices of the entity are situated:

19. Markets Served by the Entity:

IV. Employees:

20. Details as at March 31, 2025:

b. Differently abled Employees and Workers

21. Participation/ Inclusion/ Representation of Women:

22. Turnover rate for permanent employees and workers:

V. Holding, Subsidiary and Associate Companies (including joint ventures):

23. (a). Names of holding/ subsidiary/ associate companies/ joint ventures

VI. CSR (Corporate Social Responsibility) Details:

Transparency and Disclosures Compliances:

25. Complaints/ Grievances on any of the Principles (1-9) under the National Guidelines on Responsible Business Conduct:

26. Overview of the entity’s material responsible business conduct issues

Section B: Management and Process Disclosures

Governance, leadership, and oversight

Section C: Principle Wise Performance Disclosure

Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent, and Accountable

Essential Indicators

3. Of the instances disclosed in Question 2, above detail of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide web-link to the policy.

9. Openness of Business:

Leadership Indicators

1. Awareness programmes conducted for the value chain partners on any of the Principles during the financial year 2024-25:

Essential Indicators

Leadership Indicators

Essential Indicators

1. a. Details of measures for the well-being of Employees:

1. b. Details of measures for the well-being of Workers:

1. c. Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format

2. Details of retirement benefits, for Current FY 2023- 24 and Previous FY 2022- 23

3. Accessibility of Workplaces

If “Not”, then whether any steps are being taken by the entity in this regard.

7. Membership of employees and workers in association(s) or Unions recognized by the listed entity:

8. (a). Details of training given to employees and workers on “Health and Safety Measures”

(b). Details of training given to employees and workers on “Skill Upgradation”

9. Details of Performance and Career Development reviews of employees and workers:

10. Heath and Safety Management System:

11. Details of safety related incidents, in the following format:

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

13. Number of complaints on the following made by employees and workers:

14. Assessment for the Year (2024-25):

Leadership Indicators

1. Does the entity extend any life insurance or compensatory package in the event of death of (A). Employees; and (B). Workers (Yes/No). Provide detail.

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/No)

5. Details on assessment of value chain partners (FY 2024-25):

6. Provide details of any corrective actions taken or underway to address significant risks/ concerns arising from assessments of health and safety practices and working conditions of value chain partners.

Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders. Essential Indicators

1. Describe the process for identifying key stakeholder groups of the entity.

2. List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.

Leadership Indicators

If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.

3. Provide detail of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

Principle 5: Businesses should respect and promote human rights.

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:

2. Details of minimum wages paid to employees and workers, in the following format:

3. Details of remuneration/ salary/ wages, in the following format for FY 2024-25:

a. Median remuneration/ wages:

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

6. Number of complaints on the following made by employees and workers:

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 in the following format:

Pfizer Ltd. Environmental & Social Information 2025